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1. Abbreviations 
 
ARF    ADP-ribosylation factor 
BCA    2,2'-Bischinoline-4,4'-dicarbonic acid 
BSA    Bovine serum albumin 
DAG    Diacylglycerol 
DMEM   Dulbecco's modified Eagle's medium 
DMSO   Dimethylsulfoxide 
DNase    Deoxyribonuclease 
dNTP    2'-Deoxyribonucleoside-5'-triphosphate 
DTT    1,4-Dithiothreitol 
EGF    Epidermal growth factor 
FCS    Fetal calf serum 
GAP    GTPase-activating protein 
GEF    Guanine nucleotide exchange factor 
GFP    Green fluorescent protein 
G protein   Guanine nucleotide-binding protein 
GST    Glutathione S-transferase 
GTPgS    Guanosine-5'-O-[g-thio]-triphosphate 
HA    Influenza hemagglutinin epitope tag 
HBSS    Hank's balanced salt solution 
HeBS    HEPES-buffered solution 
HEK-293 cells   Human embryonic kidney 293 cells 
HEPES   N-(2-Hydroxyethyl)-piperazine-N'-2-ethanesulfonic acid 
IP3    Inositol-1,4,5-trisphosphate 
IPTG    Isopropyl-b-D-thiogalactopyranoside 
LPA    Lysophosphatidic acid 
mAChR   Muscarinic acetylcholine receptor 
MOI    Multiplicity of infection 
PA    Phosphatidic acid  
PAGE    Polyacrylamide gel electrophoresis 
PBS    Phosphate-buffered saline 
PDGF    Platelet-derived growth factor 
PH    Pleckstrin homology 
PIP 5-kinase   Phosphoinositide-4-phosphate 5-kinase 
PIP2    Phosphatidylinositol-4,5-bisphosphate 
PIP3    Phosphatidylinositol-3,4,5-trisphosphate 
PKC    Protein kinase C 
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PKN    Protein kinase N 
PLC    Phospholipase C 
PLD    Phospholipase D 
PMA    Phorbol 12-myristate 13-acetate 
PMSF    Phenylmethyl sulfonylfluoride 
PtdCho   Phosphatidylcholine 
PtdEtOH   Phosphatidylethanol 
PTX    Pertussis toxin 
PX    Phox homology 
RBD    Rho-binding domain of Rhotekin 
RGS    Regulators of G protein signaling 
RNase    Ribonuclease 
SDS    Sodium dodecylsulfate 
TBE    Tris-borate-EDTA 
TBS    Tris-buffered saline 
TCA    Trichloroacetic acid 
TE    Tris-EDTA 
TEMED   N,N,N',N'-Tetramethylethylenediamine 
TNM-FH   Trichoplusiani nutrient medium-formulation hink 
Tris    Tris-(hydroxymethyl)-aminomethane 
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2. Introduction 
 
2.1 Phospholipase D and signal transduction 
 
The hydrolysis of cellular phospholipids leads to the formation of various bioactive lipid 
mediators, acting either as extracellular signaling molecules or as intracellular second messengers. A 
well-known second messenger-forming system involving phospholipid hydrolysis is the stimulation of 
phosphoinositide-specific phospholipase C (PLC) isoforms, (Rhee, 2001). Upon activation by 
membrane receptors, these PLC enzymes hydrolyze the membrane phospholipid, 
phosphatidylinositol-4,5-bisphosphate (PIP2), and thereby generate the two second messengers, 
diacylglycerol (DAG) and inositol-1,4,5-trisphosphate (IP3), leading to the activation of several 
protein kinase C (PKC) isoforms and the release of Ca2+ from intracellular stores, respectively. It is 
now well established that PLC stimulation plays a major role in many early and late cellular 
responses to receptor activation, including smooth muscle contraction, secretion, neuronal signaling 
as well as cell growth and differentiation (Clapham, 1995; Nishizuka, 1995; Newton, 1997; 
Berridge et al., 2000; Battaini, 2001).  
In 1948, Hanah and Chaikoff were the first to discover phospholipase D (PLD) as a 
distinct, phospholipid-specific phosphodiesterase activity in cabbage leaves. Their pioneering work 
indicated that PLD hydrolyzes phosphatidylcholine to phosphatidic acid (PA) and choline (Figs. 1 
and 2). However, only in the mid-1980s, the fundamental discovery that PLD is rapidly and 
dramatically activated in response to extracellular stimuli in cultured animal cells has brought PLD 
signaling to the very forefront of current biological and biomedical research (Exton, 1999; Liscovitch 
et al., 2000; Cockcroft, 2001; Steed & Cow, 2001; Exton, 2002). Thus, PLD was classified, 
together with phosphoinositide-specific PLC isoforms, as a bona fide signal-activated 
phospholipase, generating biologically active products which were expected to play important roles 
in the regulation of cell function and cell fate. Meanwhile, phosphatidylcholine-hydrolyzing PLD has 
been identified in bacteria, protozoa, fungi, plants and animals, and, due to this widespread 
distribution, is generally assumed to be involved in the regulation of fundamental cellular functions. 
Indeed, activation of PLD by a vast number of membrane receptors has now been established to 
modulate a wide array of cellular responses, such as calcium mobilization, secretion, superoxide 
production, endocytosis, exocytosis, vesicle trafficking, glucose transport, rearrangements of the 
actin cytoskeleton, mitogenesis and apoptosis (Daniel et al., 1999; Jones et al., 1999a; McPhail et 
al., 1999; Venable et al., 1999; Nakashima & Nozawa, 1999; Liscovitch et al., 2000; Exton, 
2002; Cummings et al., 2002a; Joseph et al., 2002). 
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Fig. 1: Regulation of PLD enzymes and cellular roles of PA. For further explanation, see text. 
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2.2 Cellular roles of phosphatidic acid 
 
The regulation of cellular responses by PLD is likely mediated by its immediate reaction 
product PA (English, 1996). PA has been demonstrated to bind to various cellular proteins, such as 
Raf-1 kinase, protein phosphatase 1 and the mammalian target of rapamycin, probably affecting both 
cellular localization and activity of these PA-binding proteins (Ghosh et al., 1996; Kishikawa et al., 
1999; Rizzo et al., 2000; Fang et al., 2001; Manifava et al., 2001; Jones & Hannun, 2002). 
Furthermore, PA can be metabolized to DAG by phosphatidate phosphohydrolase and to 
lysophosphatidic acid (LPA) by phospholipase A2 (Dennis, 1994; Sciorra & Morris, 1999). While 
PA-derived DAG is believed to stimulate a specific subset of PKC isoforms (Pettitt et al., 1997; 
Hodgkin et al., 1998), LPA acts as an extracellular signaling molecule, activating specific 
heptahelical receptors coupled to heterotrimeric guanine nucleotide-binding proteins (G proteins) 
(Contos et al., 2000; Fukushima et al., 2001). Thus, due to the formation of various bioactive lipid 
mediators (PA, DAG and LPA), regulation of cellular functions by PLD can involve complex 
signaling networks. 
A role for PLD in actin organization has initially been observed upon addition of bacterial 
PLD from Streptomyces chromofuscus and exogenous PA to IIC9 fibroblasts (Ha & Exton, 
1993). As exogenous PA can be metabolized to LPA (van Dijk et al., 1998), the question of 
whether the effects are directly mediated by PA or via generation of LPA is still not definitively 
answered. Primary alcohols have proven useful tools to test the involvement of PLD in cellular 
processes. These alcohols, such as ethanol and butan-1-ol, decrease PA formation by shunting 
phosphatidyl moieties into biologically inactive phosphatidylalcohols (Fig. 2).For example, treatment 
of porcine aortic endothelial cells as well as human airway epithelial cells with butan-1-ol reduced 
agonist-stimulated formation of actin stress fibres (Cross et al., 1996; Porcelli et al., 2002). Primary 
alcohols further inhibited agonist-induced secretion of interleukin-8 from and activation of 
extracellular signal-regulated kinase in human bronchial epithelial cells, calcium mobilization in U937 
cells, activation of p38 mitogen-activated protein kinase in HL-60 cells, phosphorylation of p22phox 
[a subunit of flavocytochrome b558 of the superoxide-generating NADPH oxidase] in human 
neutrophils, activation of phosphoinositide 3-kinase and Akt in CHO cells, activation of type Ia 
phosphatidyl-4-phosphate (PIP) 5-kinase in porcine aortic endothelial cells, secretion of 
metalloproteinase-9 from human fibrosarcoma cells, release of noradrenaline from chromaffin cells 
and extracellular signal-regulated kinase-driven mitogenesis in NIH 3T3 cells (Caumont et al., 1998; 
Melendez et al., 1998; Williger et al., 1999a; Caumont et al., 2000; Jones et al., 2000; Regier et 
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al., 2000; Banno et al., 2001; Bechoua & Daniel, 2001; Hong et al., 2001; Cummings et al., 
2002b; Wang et al., 2002). Inhibition of PA formation also interfered with the recruitment of the 
coatomer complex during formation of transport vesicles (Ktistakis et al., 1996; Bi et al., 1997; 
Chen et al., 1997; Jones et al., 1999b), but the importance of PLD in the budding of COP1-coated 
vesicles has been questioned by more recent findings (Kuai et al., 2000). Taken together, these 
findings strongly support an essential role for PLD in a variety of cellular functions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2: Transphosphatidylation reaction catalyzed by PLD enzymes. For further explan-ation, 
see text. 
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2.3 PLD isoforms 
 
Several PLD genes have recently been cloned, and a PLD gene superfamily, characterized 
by a number of structural domains and sequence motifs, has emerged. The PLD superfamily includes 
bacterial phosphatidylserine and cardiolipin synthases, bacterial endonucleases, pox virus envelope 
proteins and a murine toxin from Yersenia pestis (Koonin, 1996; Ponting & Kerr, 1996; Stuckey & 
Dixon, 1999; Frohman et al., 1999; Exton, 1999; Leiros et al., 2000; Liscovitch et al., 2000; 
Exton, 2002). In mammalian cells, two PLD isoforms, PLD1 and PLD2, have been identified as 
mediators of cellular signaling. Additional PLD activities have been described, such as an oleate-
activated PLD and phosphoinositide-specific PLD enzymes, but their contribution to the regulation of 
cellular signaling is not well understood (Ching et al., 1999; Liscovitch et al., 2000; Cockcroft, 
2001; Exton, 2002; Cummings et al., 2002a). 
Mammalian PLD1 cDNA, encoding a 1074-amino acid protein, was initially cloned from a 
HeLa cell cDNA libary, whereas the splice variant PLD1b, encoding a 1036-amino acid protein, 
was identified by quantitative reverse transcriptase PCR in HL-60 cells (Hammond et al., 1995; 
Morris et al., 1996; Hammond et al., 1997; Colley et al., 1997a; Sung et al., 1999a). The 
identification of related sequences in expressed sequence databases resulted in the cloning of PLD2, 
encoding a 933-amino acid protein and sharing 55 % identity to PLD1 (Colley et al., 1997b; Redina 
& Frohman, 1998; Sung et al., 1999b). PLD1 and PLD2 contain the four highly conserved domains 
I-IV and other motifs (see Fig. 14). The domains I and IV bear NH2- and COOH-terminally located 
HKD motifs, which have been shown to be essential for catalytic activity (Sung et al., 1997), 
whereas conserved regions in domain III and the COOH-terminus are required to gain full activation 
of PLD enzymes (Sung et al., 1999a,b; Xie et al., 2000). At the NH2-terminus, PLD1 and PLD2 
comprise a pleckstrin homology (PH) domain as well as a phox homology (PX) domain. PH and PX 
domains modulate the intracellular localization and activity state of a large number of proteins 
involved in signal transduction, apparently due to interaction with phosphoinositides, especially PIP2 
and phosphatidylinositol-3,4,5-trisphosphate (PIP3) (Kavran et al., 1998; Hirata et al., 1998; 
Teruel & Meyer, 2000; Cullen et al., 2001; Sato et al., 2001; Xu et al., 2001). These 
phosphoinositide-binding motifs also modulate the membrane association and activity of PLD 
enzymes (Hodgkin et al., 2000; Sciorra et al., 1999). PLD1, but not PLD2, contains a 116-amino 
acid loop, and it has been proposed that this sequence may mediate interaction of PLD1 with 
negative regulatory elements (Sung et al., 1999a,b). In addition, specific direct interaction sites for 
several signaling components have been identified on PLD enzymes, which may contribute to enzyme 
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regulation (see below; Exton, 1999; Cockcroft, 2001; Liscovitch et al., 2001; Exton, 2002; 
Cummings  et al., 2002a). Based on this molecular analysis, catalytically inactive mutants have very 
recently been generated, K898R PLD1 and K758R PLD2, respectively, which have been 
successfully used to further reveal the physiological role of PLD enzymes in mammalian cells. Using 
this approach, both PLD1 and PLD2 were shown to be required for endocytosis of the epidermal 
growth factor (EGF) receptor in 3Y1 rat fibroblasts (Shen et al., 2001). Furthermore, PLD2 was 
found to be essential for apical constitutive protein transit, whereas PLD1 was implicated in agonist-
triggered apical secretion in HT29-cl19A cells (Denmat-Ouisse et al., 2001). Microinjection of 
catalytically inactive PLD1 in Aplysia neurons reduced the release of  acetylcholine (Humeau et al., 
2001), and expression of catalytically inactive PLD1 largely reduced catecholamine secretion from 
stimulated chromaffin and PC12 cells (Vitale et al., 2001). Finally, expression of catalytically inactive 
PLD1 reduced agonist-induced formation of actin stress fibers in Rat-2 fibroblasts and COS-7 cells 
(Kam & Exton, 2001). Thus, the use of catalytically inactive PLD mutants represents an attractive 
tool to study the physiological importance of PLD enzymes in various cell types. However, in many 
mammalian cells, specifically in primary cultured cells, e.g. cardiomyocytes, this approach is 
hampered due to low transfection efficiencies. 
 
2.4 Subcellular localization of PLD isoforms 
 
The subcellular localization of PLD isoforms was studied by enzyme activity analysis and 
Western blotting of subcellular fractions, immunochemistry and expression of epitope-tagged PLD 
enzymes in several cell types. PLD was found at the plasma membrane as well as in intracellular 
compartments, including the endoplasmic reticulum, the Golgi compartment, endosomes and 
lysosomes (Cockcroft, 2001; Liscovitch et al., 2001; Exton, 2002). Using immunofluorescence, 
immunogold electron microscopy and subcellular fractionation, endogenous PLD1 was found to 
primarily localize to the Golgi apparatus in GH3 pituitary and NRK kidney cells (Freyberg et al., 
2001). Other studies have localized PLD1 to vesicular structures in the perinuclear region, to the 
plasma membrane, Golgi or endosomes (Colley et al., 1997a; Brown et al., 1998; Kim et al., 
1999; Emoto et al., 2000; Hughes & Parker, 2001; Kam & Exton, 2001; Kristiansen et al., 2001; 
Lee et al., 2001; Vitale et al., 2001; Hughes et al., 2002). Thus, while PLD1 seems to be 
associated with various intracellular compartments in mammalian cells, PLD2 has been primarily 
localized to the plasma membrane (Colley et al., 1997b; Emoto et al., 2000; Park et al., 2000; Lee 
et al., 2001). Both PLD enzymes have also been shown to constitutively associate with membrane 
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receptors, and it is speculated that this binding might relocate PLD to the plasma membrane (Min et 
al., 1998; Slaaby et al., 1998). In line with this, PLD1 and PLD2 have been reported to be present 
in caveolae (Czarny et al., 1999; Sciorra & Morris, 1999), which represent, together with lipid rafts, 
compartimentalized membrane signaling microdomains, believed to confer specificity into the 
complex mechanisms of signal transduction (Okamoto et al., 1998; Kurzchalia & Parton, 1999; 
Anderson & Jacobson, 2002; Zajchowski & Robbins, 2002). Finally, the association of PLD1 with 
the detergent-insoluble cytoskeleton has been reported (Iyer & Kusner, 1999; Hodgkin et al., 
1999). Lee et al. (2001) reported recently colocalization of PLD1 and PLD2 with the actin 
cytoskeleton in the periphery of COS-7 cells and PC12 cells. In addition, posttranslational 
modification of PLD enzymes apparently altered its subcellular localization and may thus affect PLD-
dependent signaling as well (Rudge et al., 1998; Exton, 2002). 
 
2.5 Regulation of PLD by membrane receptors 
 
As mentioned above, in the presence of primary alcohols, PLD enzymes catalyze a 
transphosphatidylation reaction, generating specific phosphatidylalcohols. Due to their unique origin 
and their relative metabolic stability, the formation of phosphatidylalcohols has served as a 
convenient and sensitive marker for PLD activation in cultured cells (Morris et al., 1997). Signal-
dependent PLD activation has been demonstrated in numerous cell types stimulated with a variety of 
hormones, neurotransmitters, growth factors, cytokines, adhesion molecules, drugs and physical 
stimuli (Exton, 1999; Cockcroft, 2001; Liscovitch et al., 2000; Exton, 2002). As nearly every 
membrane receptor known to stimulate PIP2-specific PLC isoforms also caused PLD stimulation, it 
was assumed that stimulation of PLD might be secondary to PLC activation and actually initiated by 
the increase in cytosolic Ca2+ concentration and activation of PKC isoforms. The 12 PKC isoforms 
currently known are classified according to their differential Ca2+ and DAG requirements: 
Ca2+/DAG-dependent conventional PKC enzymes (e.g. PKC-a and PKC-b), DAG-dependent 
novel PKC enzymes and Ca2+/DAG-independent atypical PKC enzymes. Isoform-specific PKC 
inhibitors and down-regulation (inactivation) of DAG-dependent PKC isoforms by long-term cell 
treatment with phorbol esters, such as phorbol 12-myristate 13-acetate (PMA), were used to study 
the involvement of PKC isoforms in PLD activation (Newton, 1997; Battaini, 2001). Indeed, PLD 
responses to EGF and platelet-derived growth factor (PDGF), activating on tyrosine kinase 
receptors, as well as LPA and carbachol, acting on G protein-coupled receptors, turned out to be 
PKC-dependent in some cell types (Exton, 1999; Caulfield & Birdsall, 1998; Contos et al., 2000; 
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Schlessinger, 2000; Cockcroft, 2001; Liscovitch et al., 2001; Exton, 2002; Fukushima et al., 
2001). Likewise, in mouse embryo fibroblasts lacking PLC-g1, known to be primarily activated by 
tyrosine kinase receptors, stimulation of PLD by PDGF was largely reduced (Hess et al., 1998; 
Hess et al., 2000; Schlessinger, 2000; Rhee, 2001). Furthermore, a physical association of PLD 
with PKC-a and PKC-b  has been reported, resulting in strong activation of in vitro PLD1, but not 
PLD2, activity. Mutagenesis and binding studies identified the major interaction site between PLD1 
and PKC-a within the NH2-terminus of PLD1 (Park et al., 1998; Slaaby et al., 2000). Based on 
the molecular characterization of the PLD1/PKC-a interaction site, PLD1 mutants unresponsive to 
PKC have been generated which, upon expression in HEK-293 cells, did not respond to activation 
of coexpressed bombesin and M1 or M3 muscarinic acetylcholine receptors (mAChRs) (Zhang et 
al., 1999; Du et al., 2000). PKC activation by bombesin and M1/M3 muscarinic receptors is 
primarily caused by the stimulation of PLC-b  isoforms by pertussis toxin (PTX)-insensitive Gaq 
proteins (Neer, 1995; Gudermann et al., 1996; Caulfield & Birdsall, 1998; Rhee, 2001; Watling, 
2001). In line with this, expression of the PKC-unresponsive PLD1 mutant in COS-7 cells resulted 
in PLD activity which was no longer responsive to constitutively active Gaq (Xie et al., 2002). 
The M3 mAChR, stably expressed in HEK-293 cells, was shown to couple to both PLC 
and PLD via a PTX-insensitive mechanism (Peralta et al., 1988; Offermanns et al., 1994; Schmidt 
et al., 1994), however, stimulation of PLD by the agonist carbachol was found to be not affected by 
PKC inhibition (Schmidt et al., 1994; Rümenapp et al., 1997). Likewise, PLD stimulation by the 
a1-adrenoceptor in Mardin-Darby canine kidney cells and in rabbit aortic vascular smooth muscle 
cells was shown to be PKC-independent (Kiss, 1996; Balboa & Insel; 1998; Muthalif et al., 2000; 
Parmentier et al., 2001), strongly indicating that PLD stimulation by membrane receptors must not 
necessarily be secondary to PLC stimulation. 
G protein-coupled receptors constitute the largest group of membrane receptors known to 
regulate a wide range of biological responses, including cell growth, differentiation, migration and 
inflammatory processes (Morris & Malbon, 1999; Lefkowitz, 2000; Marinissen & Gutkind, 2001; 
Pierce et al., 2002). These receptors induce cellular signaling via GTP-bound a-subunits, classified 
into the four families, Gs, Gi, Gq and G12, as well as free bg-dimers (Neer, 1995; Gudermann et al., 
1996; Wieland et al., 1997; Lefkowitz, 2000; Marinissen & Gutkind, 2001; Pierce et al., 2002). 
a-Subunits of Gs and Gi proteins, but not members of the Gq and G12 families, are targets for the 
bacterial toxins, cholera toxin from Vibrio cholerae, which specifically ADP-ribosylates Gas 
proteins, leading to their persistent activation, and PTX from Bordetella pertussis, which ADP-
ribosylates Ga i proteins, causing their inactivation (Neer, 1995). These toxins have been used to 
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characterize G protein-coupled receptor signaling to PLD. PLD stimulation by chemoattractants in 
neutrophils and by the LPA-like lysophospholipid sphingosine-1-phosphate in human bronchial 
epithelial cells was PTX-sensitive (Fensome et al., 1998; Watling, 2001; Cummings et al., 2002b; 
Wang et al., 2002). As mentioned above, M3 mAChR signaling to PLD in HEK-293 cells as well as 
PLD stimulation by endothelin-1, thrombin and noradrenaline in neonatal rat cardiomyocytes was 
mediated via PTX-insensitive G proteins (Offermanns et al., 1994; Schmidt et al., 1994; Fahimi-
Vahid et al., 2002; Gosau et al., 2002). PLD activation by angiotensin II in vascular smooth muscle 
cells was PTX-insensitive too, but also bg-subunits were found to modulate the receptor response 
(Ushio-Fukai et al., 1999). Likewise, PLD stimulation by endothelin-1 in rat myometrium was 
controlled by both a-subunits of PTX-insensitive G proteins as well as by bg-subunits (Le Stunff et 
al., 2000a). Treatment with PTX does not discriminate between members of the Gq and G12 family 
of heterotrimeric G proteins, as both are PTX-insensitive (Neer, 1995; Dhanasekaran & Dermott, 
1996; Gudermann et al., 1996; Fields & Casey, 1997). G12 proteins have also been suggested to be 
involved in PLD regulation (Plonk et al., 1998). Recently, regulators of G protein signaling (RGS) 
have been identified as GTPase-activating proteins (GAPs), promoting GTP hydrolysis and 
deactivation of a-subunits, resulting in the inhibition of agonist responses (Druey et al., 1996; 
Dohlman & Thorner, 1997; Wieland & Chen, 1999; de Vries et al., 2000; Ross & Wilkie, 2000). 
While inhibition of receptor signaling to PLC by RGS proteins has been reported (Huang et al., 
1997; Neill et al., 1997), RGS proteins have not yet been used to study G protein-coupled receptor 
signaling to PLD. 
The question of whether PLD1 and PLD2 are differentially activated by receptors has been 
addressed only in a few reports. For example, Zhang et al. (1999) reported PLD1 stimulation by the 
Gq-coupled bombesin and M1/M3 receptors, upon coexpression in HEK-293 cells. Furthermore, 
coexpression of PLD1 together with the AT1 receptor as well as the Edg4 receptor resulted in PLD 
stimulation by angiotensin II and LPA, respectively (Du et al., 2000). These studies suggested that G 
protein-coupled receptors may couple primarily to PLD1. However, Parmentier et al. (2001) have 
reported recently that the a1-adrenoceptor signals to PLD2 in rabbit aortic smooth muscle cells. In 
addition, it has been shown recently that sphingosine-1-phosphate signaling in human bronchial 
epithelial cells may involve both, PLD1 and PLD2 (Wang et al., 2002). Thus, G protein-coupled 
receptor signaling to the two PLD isoforms needs to be further analyzed. 
Earlier reports employing tyrosine kinase inhibitors, such as genistein and tyrphostins, 
implicated that tyrosine kinase activity may affect some PLD responses (Schmidt et al., 1994; 
Rümenapp et al., 1998; Houle & Bourgoin, 1999; Le Stunff et al., 2000b; Fahimi-Vahid et al., 
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2002; Gosau et al., 2002). Indeed, Marcil et al. (1997) reported tyrosine phosphorylation of PLD1 
in HL-60 cells, but the posttranslational modification did not change enzyme activity. More recent 
studies have supplied some insights in PLD stimulation by tyrosine kinase receptors. In Rat-1 
fibroblasts expressing the human insulin receptor, the PLD response to insulin was reported to be 
mediated by PLD2, but not PLD1 (Rizzo et al., 1999), whereas in HEK-293 cells the insulin 
response was mediated by both PLD1 and PLD2 (Slaaby et al., 2000). Neither study analyzed 
whether activation of PLD by the insulin receptor was accompanied by tyrosine phosphorylation of 
the enzymes. Cotransfection of HEK-293 cells with PLD1 or PLD2 together with the EGF receptor 
resulted in activation of both PLD enzymes by EGF, but only PLD2 became tyrosine phosporylated 
upon receptor activation and associated with the EGF receptor in a ligand-independent manner. 
However, mutation of the tyrosine phosphorylation site in PLD2 did not affect the ability of EGF to 
activate the enzyme (Slaaby et al., 1998). Interestingly, it has been recently shown in HeLa cells that 
PLD1b is not simply localized in endosomes, but is relocated in these endosomal compartments after 
EGF stimulation (Hughes et al., 2002). Finally, stimulation of PLD1 by PDGF has been reported in 
Swiss 3T3 fibroblasts, which was accompanied by tyrosine phosphorylation of PLD1 and its 
physical association with the PDGF receptor (Min et al., 1998). Taken together, whereas the 
stimulation of PLC-g isoforms by tyrosine kinase receptors has been characterized in detail, our 
understanding of receptor coupling to PLD is still incomplete. 
 
2.6 Interaction of PLD with phosphoinositide metabolism 
 
In contrast to PLC-g isoforms, where direct interaction with tyrosine kinase receptors is 
needed and sufficient for activation (Schlessinger, 2000; Rhee, 2001), association of PLD enzymes 
with tyrosine kinase receptors did not trigger enzyme activity (Min et al., 1998; Slaaby et al., 1998). 
Thus, it has been assumed that receptor regulation of PLD may involve additional signaling molecules 
(Liscovitch et al., 2000; Cockcroft, 2001; Exton, 2002). Attractive candidates are 
phosphoinositides, especially PIP2 and PIP3, which profoundly affect the enzyme activity and cellular 
localization of PLD1 and PLD2 (Brown et al., 1993; Liscovitch et al., 1994; Pertile et al., 1995; 
Ohguchi et al., 1996a; Schmidt et al., 1996a; Schmidt et al., 1996b; Hodgkin et al., 1999; 
Hodgkin et al., 2000). Thus, reduction of the cellular phosphoinositide content by fodrin (Lukowski 
et al., 1996) or synaptojanin (Chung et al., 1997) inhibited PLD activities. The actin-binding protein 
fodrin most likely reduced the cellular content of PIP2 and PIP3 by inhibition of phosphoinositide 
kinases (Lukowski et al., 1998), which generate PIP2 and PIP3 by sequential phosphorylation of PI 
  2. Introduction 
 13
at the 3, 4 or 5 position of the inositol ring (Fruman et al., 1998; Anderson et al., 1999; Chan et al., 
1999; Rameh & Cantley, 1999; Vanhaesebroeck et al., 2001), whereas synaptojanin acts as a 
phosphoinositide phosphatase (Chung et al., 1997; Lee et al., 1997; Majerus et al., 1999; Lee et 
al., 2000; Toker, 2002). Phosphoinositide kinases and PLD might directly cooperate in the control 
of cellular processes. So was the coupling of phosphoinositide phosphorylation and PLD activation 
found to be necessary to initiate clathrin-coat assembly in rat brain lysosomes (Arneson et al., 
1999). Divecha et al. (2000) demonstrated that both PLD1 and PLD2 interact with type Ia PIP 5-
kinase, but only PLD2 activity was regulated by coexpression with the lipid kinase. By binding to 
proteins with PH/PX domains, PIP2 and PIP3 modulate a remarkable number of cellular processes, 
such as clathrin-coated endocytosis, vesicular trafficking, membrane movement and actin 
cytoskeleton assembly (Martin, 1998; Toker, 1998; Janmey et al., 1999; Czech, 2000; Martin, 
2001; Simonsen et al., 2001; Lemmon et al., 2002). Intriguingly, PLD enzyme activity, primarily 
PLD2, is modulated by b-actin, the actin- binding protein, a-actinin, as well as proteins involved in 
synaptic vesicle trafficking, such as AP180 [previously named clathrin assembly protein 3], 
amphiphysins, synucleins and collapsin response mediator protein-2 (Lee et al., 1997; Jenco et al., 
1998; Lee et al., 2000; Park et al., 2000; Lee et al., 2001; Ahn et al., 2002; Lee et al., 2002). 
Thus, these findings suggest that PLD enzymes may be implicated in various phosphoinositide-driven 
cellular transport processes. 
 
2.7 Regulation of PLD by monomeric GTPases 
 
The superfamily of monomeric GTPases with molecular masses of approximately 20 kDa 
consists of more than 100 members, which are divided into five groups: Ras, Ran, Rho, Rab and 
ADP-ribosylation factor (ARF) GTPases (Hall, 2000; Takai et al., 2001). These GTPases control 
distinct fundamental processes. Ras proteins primarily regulate gene expression (Feig et al., 1996; 
Vjtek & Der, 1998; Reuther & Der, 2000), Rho proteins control actin cytoskeleton organization 
(Hall, 1998; Schmidt & Hall, 1998; KjØller & Hall, 1999; Schmitz et al., 2000), Rab and ARF 
proteins are involved in the regulation of intracellular transport and membrane trafficking (Moss & 
Vaughan, 1998; Chavrier & Goud, 1999; Donaldson & Jackson, 2000), and Ran proteins in the 
regulation of nucleocytoplasmic transport and microtubule organization (Hall, 2000; Takai et al., 
2001). The cycling of monomeric GTPases from their GDP-bound inactive state to their GTP-bound 
active state is catalyzed by specific guanine nucleotide exchange factors (GEFs), whereas the 
recycling to the GDP-bound inactive state is promoted by GAPs (Hall, 2000; Jackson & Casanova, 
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2000; Reuther, & Der, 2000; Takai et al., 2001; Zheng, 2001). 
Members of the monomeric GTPases, specifically ARF, Rho and Ras proteins, play an 
important role in PLD signaling. ARF proteins, particularly ARF1 and ARF6, initially identified as in 
vitro regulators of PLD activity (Brown et al., 1993; Cockcroft et al., 1994), are now well 
established activators of both PLD enzymes, but PLD1 is much more responsive to ARF than PLD2 
(Hammond et al., 1997; Redina & Frohman, 1998; Sung et al., 1999a; Sung et al., 1999b). 
However, the evidence for a participation of ARF proteins in receptor-mediated PLD stimulation is 
largely indirect. It is mainly based on in vitro reconstitution studies with membranes and ARF-
depleted permeabilized cells (Houle et al., 1995; Rümenapp et al., 1995; Shome et al., 1997; 
Caumont et al, 1998; Shome et al., 1998; Caumont et al, 2000) and on studies with the ARF-
binding protein, Arfaptin (Kanoh et al., 1997; Tsai et al., 1998; Williger et al., 1999b). 
Furthermore, PLD stimulation by various receptors in intact cells was found to be reduced by 
brefeldin A, an inhibitor of some ARF-specific GEFs (Rümenapp et al., 1995; Karnam et al., 1997; 
Shome et al., 1997; Bacon et al., 1998; Fensome et al., 1998; Mitchell et al., 1998; Shome et al., 
1998; Rizzo et al., 1999; Andresen et al., 2000; Fahimi-Vahid et al., 2002). Similarly, the ARF-
related protein ARP, which can sequester ARF-specific GEFs, was shown to inhibit M3 mAChR 
signaling to PLD in HEK-293 cells (Schürmann et al., 1999). It should also be noted that ARF1 and 
ARF6 may indirectly modulate PLD signaling by activation of PIP 5-kinase, thus by the supply of the 
PLD cofactor PIP2 (Martin et al., 1996; Godi et al., 1999; Honda et al., 1999; Jones et al., 2000; 
Skippen et al., 2002). Likewise, it has recently been shown that ARF1 reversed the inhibition of 
PLD, particularly of PLD2, by b-actin and a-actinin which bind PIP2 (Park et al., 2000; Lee et al., 
2001). 
Rho GTPases, in particular Rho, Rac and Cdc42, exclusively activate PLD1 by direct 
interaction with its COOH-terminus, and this activation can be triggered by PKC-a and ARF1 
(Hammond et al., 1997; Colley et al., 1997a; Sung et al., 1999a,b; Frohman, et al., 2000; Cai & 
Exton, 2001). C3 transferase from Clostridium botulinum, known to specifically inactivate Rho by 
ADP-ribosylation (Aktories & Just, 1993), and the expression of inactive Rho mutants have been 
used to study the involvement of Rho in receptor signaling to PLD. Using these approaches, Rho 
was found to be involved in PLD stimulation by bradykinin and sphingosine-1-phosphate in human 
adenocarcinoma A459 cells, by PDGF and LPA in Rat-1 fibroblasts and by RANTES in Jurkat T 
cells (Malcolm et al., 1996; Hess et al., 1997; Meacci et al., 1999; Bacon et al., 1998), whereas 
apparently both, Rho and Rac, mediated tyrosine kinase receptor (PDGF and EGF) signaling to 
PLD in Rat-1 fibroblasts (Hess et al. ,  1997). In HEK-293 cells, C3 transferase specifically 
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suppressed the PLD response to the M3 mAChR, without changing PLD stimulation by tyrosine 
kinase receptors (Schmidt et al., 1999; Voß et al., 1999). The selective involvement of Rho in 
mAChR signaling to PLD in HEK-293 cells was confirmed by studies with Clostridium difficile 
toxin B, known to inactivate Rho proteins by monoglucosylation (Just et al., 1995), and further work 
identified RhoA as the essential GTPase (Schmidt et al., 1996a; Rümenapp et al., 1998; Schmidt et 
al., 1998; Schmidt et al., 1999). Since then, toxin B has been widely used to analyze the role of Rho 
proteins in receptor signaling to PLD (Ojio et al., 1996; Ohguchi et al., 1996b; Ohguchi et al., 
1997; Fahimi-Vahid et al., 2002; Gosau et al., 2002). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3: Regulation of PLD stimulation by the M3 mAChR in HEK-293 cells. For further 
explanation, see text. 
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A few studies reported that both, ARF and Rho proteins, contribute to receptor signaling 
to PLD. However, the interaction between these GTPases has either not been evaluated or a 
dominant role for ARF proteins has been proposed (Karnam et al., 1997; Bacon et al., 1998; 
Fensome et al., 1998; Fahimi-Vahid et al., 2002; Gosau et al., 2002). In HEK-293 cells, the PLD 
response to the M3 mAChR, which can activate both, ARF1 and RhoA, was shown to be regulated 
in a concerted action by independent ARF and Rho pathways (Rümenapp et al., 1995; Keller et 
al., 1997; Bayer et al., 1999) (Fig. 3). In line with such a dual regulation, ARF and Rho have been 
found to localize in PLD-containing caveolae (Michaely et al., 1999; Teruel & Meyer, 2000). The 
recent identification of ARAP proteins, which can link ARF and Rho signaling pathways, may be 
helpful to further understand the mechanism of PLD regulation by these GTPases (Bar-Sagi & Hall, 
2000; Krugmann et al., 2002; Miura et al., 2002). 
Regulation of PLD by Ras GTPases (Ras and Ral) was first reported in v-Src-transformed 
Balb/c and NIH-3T3 fibroblasts (Jiang et al., 1995; Feig et al., 1996). Further work suggested that 
Ral, which can directly interact with PLD1, cooperates with ARF (Luo et al., 1997; Kim et al., 
1998; Luo et al., 1998) and Rho proteins (Frankel et al., 1999; Wilde et al., 2002) to achieve full 
PLD activation. Treatment of HEK-293 cells with Clostridium sordellii lethal toxin and 
Clostridium difficile toxin B-1470, known to inactivate Ras and Ral by monoglucosylation, 
reduced tyrosine kinase receptor, but not M3 mAChR, signaling to PLD; the toxin effects were fully 
mimicked by expression of inactive Ras and RalA. Additional work demonstrated that the Ras/Ral 
signaling cascade to PLD was dependent on a Ral-specific GEF and triggered by PKC-a (Just et 
al., 1996; Chaves-Olarte et al., 1999; Schmidt et al., 1998; Voß et al., 1999). Likewise, it was 
reported that Ras GTPases are involved in PLD responses to PDGF in NIH-3T3 and Rat-2 cells 
(Lucas et al., 2000) and RalA in EGF receptor signaling to PLD in 3Y1 rat fibroblasts (Lu et al., 
2000). Ben El Hadj et al. (1999) reported that Clostridium sordellii lethal toxin, apparently by 
inactivating endogenous Ras and Ral proteins, also interfered with G protein activation of PLD in 
HL-60 cells. Finally, extracellular signal-regulated kinase, an effector system of Ras proteins, was 
found to modulate PLD signaling (Muthalif et al., 2000; Parmentier et al., 2001; Wang et al., 2002; 
Chen et al., 2002), suggesting that Ras proteins may regulate the PLD response by this pathway.  
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2.8 Involvement of Rho-dependent kinases in PLD stimulation 
 
As mentioned above, PLD stimulation by RhoA can be caused by a direct PLD1-RhoA 
interaction. However, there is also evidence for indirect, Rho-dependent mechanisms. For example, 
inhibition of PLD by toxin B was accompanied by a reduction of the cellular PIP2 content, and 
addition of PIP2 to cell membranes could rescue this inhibition (Schmidt et al., 1996b; Schmidt et 
al., 1996c; Zhang et al., 1996; Oude Weernink et al., 2000a; Fahimi-Vahid et al., 2002; Gosau et 
al., 2002). RhoA was actually shown to stimulate the PIP2 synthesis by PIP 5-kinase in HEK-293 
cells (Oude Weernink et al., 2000b). Intriguingly, Rho-kinase, a serine/threonine kinase, which 
activity depends on GTP-loaded Rho (Leung et al., 1995; Kimura et al., 1996; Leung et al., 1996; 
Lim et al., 1996; Matsui et al., 1996; Nakagawa et al. 1996; Maekawa et al., 1999), was found 
to mediate the RhoA-dependent PLD response to the M3 mAChR (Schmidt et al., 1999) (Fig. 3), 
and to stimulate PIP 5-kinase activity as well (Oude Weernink et al., 2000b). Based on these initial 
reports, Rho-kinase was confirmed to regulate PIP 5-kinase in N1E-115 neuroblastoma cells and 
PLD-driven cell responses in Rat-2 fibroblasts and human bronchial epithelial cells (Kam & Exton, 
2001; Cummings et al., 2002b; Yamazaki et al., 2002). Rho-kinase belongs to a family of Rho 
effectors, including the PKC-related protein kinase N (PKN), rhophilin, rhotekin, p21-activated 
protein kinase (PAK) and the Wiskott-Aldrich syndrome protein (WASP), which are differentially 
regulated by Rho proteins. Whereas Rho regulates Rho-kinase, PKN, rhophilin and rhotekin, 
Rac/Cdc42 control PAK and WASP functions (Aspenström, 1999; Kaibuchi et al., 1999; Amano 
et al., 2000; Bishop & Hall, 2000). Also these Rho effectors are candidates to be involved in the 
regulation of PLD activity. Indeed, Oishi et al. (2001) recently reported that PKN regulates PLD1 
through direct interaction. As PKN also interacts with a-actinin, which by itself inhibits PLD 
enzymes, PKN may modulate PLD signaling by reversing the inhibitory effect of a-actinin on PLD1, 
as well as by direct interaction with PLD1 (Mukai et al., 1997; Lee et al., 2001). 
 
2.9 LIM-kinase 
 
PLD enzymes were not found to directly interact with, or to be phosphorylated by Rho-
kinase (Schmidt et al., 1999), indicating that regulation of PLD by Rho/Rho-kinase obviously 
involves additional, yet undefined, components. As Rho-kinase profoundly affects the reorganization 
of the actin cytoskeleton by interacting with various signaling molecules (Aspenström, 1999; 
Kaibuchi et al., 1999; Amano et al., 2000; Bishop & Hall, 2000), mechanisms involved in this 
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process may be linked to the regulation of PLD as well. Upon activation by Rho, Rho-kinase most 
likely directs the actin architecture via two mechanisms: 1) Rho-kinase phosphorylates, and thereby 
inhibits, myosin light chain phosphatase and consequently increases actomyosin-based contractility 
(Kimura et al., 1996; Amano et al., 1997; Oshiro et al., 1998; Maekawa et al., 1999), and 2) 
Rho-kinase phosphorylates the serine/threonine kinase LIM-kinase, which in turn phosphorylates 
and inactivates the actin depolymerization factor cofilin, leading to enhanced actin polymerization 
(Maekawa et al., 1999; Ohashi et al., 2000; Lou et al., 2001; Sumi et al., 2001a,b; Matsui et al., 
2002). Two LIM-kinases (LIM domain containing kinase; approximately 65 kDa) have been 
identified, which are located in the cytosol and nucleus of mammalian cells; in addition, LIM-kinase 
was found to be abundantly expressed in the peripheral and central nervous system (Mizuno et al., 
1994; Pröschel et al., 1995; Edwards et al., 1999; Meng et al., 2002). LIM-kinase bears two 
NH2-terminal LIM domains and a PDZ domain; while the LIM domains seem to modulate enzyme 
activity, the PDZ domain probably is responsible for membrane association (Edwards & Gill, 1999; 
Edwards et al., 1999). Phosphorylation of LIM-kinase at threonine 508 by Rho-kinase or PAK 
activates LIM-kinase, which in turn phosphorylates its mere substrate cofilin, leading to profound 
changes in the dynamics of the actin cytoskeleton (Arber et al., 1998; Rosenblatt & Mitchison, 
1998; Yang et al., 1998; Edwards et al., 1999; Lawler, 1999; Maekawa et al., 1999; Minamide et 
al., 2000; Sumi et al., 2001a,b; see also Fig. 4). Meanwhile, LIM-kinase has been implicated in 
several processes, including the regulation of gene transcription by the serum response factor, 
chemotaxis of T lymphocytes, mitosis of HeLa cells, Listeria-induced phagocytosis and regulation of 
the actin growth cone in neuronal cells, and is associated with the manifestation of the William-
Beuren Syndrome [a neurological condition characterized by mild mental retardation and defects in 
visu-spatial cognition] (Tassabehji et al., 1996, Wu et al., 1998; Sotiropoulos et al., 1999; Wang 
et al., 1999; Donnai & Karmiloff-Smith, 2000; Aizawa et al., 2001a; Bierne et al., 2001; Amano 
et al., 2002; Geneste et al., 2002; Nishita et al., 2002).  
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Fig. 4: LIM-kinase and cofilin signaling. For further explanation, see text. 
 
Cofilin (approximately 20 kDa), the only LIM-kinase substrate identified so far, was 
named for its ability to form cofilamentous structures with actin; it is widely expressed, in particular in 
hematopoietic cells, osteoclasts and fibroblasts. Cofilin bears an actin- and a phosphoinositide-
binding domain and a sequence confering nuclear localization (Nishida et al., 1984; Ott et al., 1996; 
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cytoskeleton dynamics during cell division, exo- and endocytosis as well as motility. It binds to actin 
monomers as well as actin filaments (F-actin), thereby promoting actin filament turnover 
(Lappalainen & Drubin, 1997; Bamburg, 1999; Higgs & Pollard, 2001; Chen et al., 2000; 
Birkenfeld et al., 2001). The cofilin-actin interaction is tightly controlled by phosphocycling. Cofilin 
preferentially binds to ADP-actin monomers and thereby inhibits the nucleotide exchange on them. 
Consequently, the actin monomer pool increases and F-actin rapidly depolymerizes. Phosphorylation 
of cofilin by LIM-kinase at serine 3, located in the actin-binding domain, results in its inactivation. 
Mutation of serine to alanine (S3A) generates a nonphosphorylatable cofilin, which is used to study 
the role of cofilin in cellular responses (Agnew et al., 1995; Bamburg, 1999; Higgs & Pollard, 2001; 
Toshima et al.; 2001; see also Fig. 4). The transient phosphorylation (inactivation) of cofilin permits 
free nucleotide exchange on actin monomers and F-actin reassembly; dephosphorylation by a cofilin 
phosphatase mobilizes cofilin for another round of actin monomer sequestering, allowing actin 
structure reorganization (Meberg et al. 1998; Bamburg, 1999; Chen et al., 2000; Higgs & Pollard, 
2001). In Drosophila, the slingshot phosphatase, a family of phosphatases that have the property of 
F-actin binding, was found to commit the reactivation of cofilin (Niwa et al., 2002). In addition, it 
has been demonstrated that phosphoinositides, the actin-related protein complex Arp2/3 and the 
modulation of intracellular pH affected the functions of cofilin (Yonezawa et al., 1985; Nagaoka et 
al., 1995; Sakisaka et al., 1997; Mullins et al., 1998; Kusano et al.,1999; Bernstein et al., 2000; 
Ono & Ono, 2002). A role for LIM-kinase and cofilin in the reorganization of the actin cytoskeleton 
by Rho/Rho-kinase is now well accepted, but it is not known whether LIM-kinase and cofilin affect 
the PLD response as well. 
 
2.10 Aims of the study 
 
Aim of the present study was to gain further insights into the regulation of PLD by the G 
protein-coupled M3 mAChR in HEK-293 cells. For comparison, the PKC-dependent tyrosine 
kinase receptor signaling to PLD in these cells was studied. In particular, it was intended 1) to define 
the type of PTX-insensitive heterotrimeric G protein mediating the M3 mAChR-induced PLD 
stimulation, in comparison to the PLC response by the same receptor, 2) to identify the PLD 
isoform(s) activated by the M3 mAChR, 3) to generate adenoviruses encoding wild-type and 
catalytically inactive PLD1 and PLD2 mutants for future work on the cellular role of these PLD 
enzymes in receptor action, and 4) to identify the components and mechanisms by which Rho/Rho-
kinase controls PLD stimulation by the M3 mAChR. 
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3. Materials and Methods 
 
3.1 Materials 
 
3.1.1 Chemical reagents 
 
Name        Source (supplier / company) 
Acetic acid       Baker 
Acrylamide      Serva 
Agarose      Invitrogen 
Ammonia      Merck 
Ammonium formiate Fluka 
Ammonium peroxodisulfate    Serva 
Ampicillin      Grünenthal 
Aprotinin      Sigma 
ATP       Roche Molecular Biochemicals 
Benzamidine      Sigma 
Bisacrylamide      Serva 
Boric acid      Merck 
Bradykinin      Sigma 
BSA       Biomol 
BSA, fatty acid free Sigma 
1-Butanol Baker 
Calcium acetate     Merck 
Calcium chloride     Merck 
Calcium dihydrogenphosphate     Merck 
Carbachol      Sigma 
Chloroform      Baker 
Chloropan      Maniatis 
Chloroquin diphosphate    Sigma 
Coomassie-blue     Serva 
Diethylether  Merck 
DMEM/Nutrient Mix F-12    Invitrogen 
DMSO      Sigma 
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DTT       Serva 
EDTA       Merck 
EGF       Biomol 
EGTA       Merck 
Ethanol       Baker 
Ethidium bromide     Sigma 
Ethylacetate      Merck 
FCS       Invitrogen 
Geneticin (G418)     Invitrogen 
GDP       Roche Molecular Biochemicals 
g-Globulin (calf)     BIO-RAD 
D(+)-Glucose      Merck 
Glutathione      Amersham 
Glycerol      Fluka 
Glycine             Sigma 
GTPgS       Roche Molecular Biochemicals 
HEPES      Serva 
Imidazole      Sigma 
Insulin       Sigma 
Iodine       Merck 
IP3       Sigma 
IPTG       Stratagene 
Isooctane      Riedel de Haen 
Isopropanol      Baker 
Kanamycin      Sigma 
LB agar      Invitrogen 
LB medium      Invitrogen 
Leupeptin      Sigma 
Lithium chloride     Merck 
LPA       Sigma 
Magnesium chloride, hexahydrate   Merck 
Magnesium sulfate, heptahydrate   Merck 
2-Mercaptoethanol     Merck 
Methanol      Baker 
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Nonidet P 40      Fluka 
PA       Sigma 
Penicillin G      Seromed 
Phenol       Fluka 
Phosphoric acid     Merck 
PMA       Sigma 
PMSF       Roche Molecular Biochemicals 
Poly-D-lysine      Sigma 
Poly-L-lysine      Seromed 
Ponceau S      Sigma 
PtdCho      Sigma 
PtdEtOH      Avanti 
PIP2       Roche Molecular Biochemicals 
Hydrochloric acid (37 %)    Merck 
SDS       Serva 
Serva-blue (G/R)     Serva 
Skim milk powder     Merck 
SOC medium      Invitrogen 
Sodium acetate     Merck 
Sodium dihydrogenphosphate    Merck 
Sodium carbonate     Merck 
Sodium chloride     Merck 
Sodium deoxycholate     Fluka 
Sodium cholate     Sigma 
Sodium bicarbonate     Merck 
Sodium hydroxide     Merck 
Soybean trypsin inhibitor    Sigma 
Streptomycin      Seromed 
Sucrose      Merck 
TCA       Merck 
TEMED      Serva 
Thrombin      Pharmingen 
TNM-FH      Sigma 
Trichlorotrifluoroethane    Merck 
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Triethanolamine     Sigma 
Tris       Merck 
TRITC-phalloidin     Sigma 
Triton X-100      Roth 
Trypsin       Invitrogen 
Tween 20      Sigma 
 
 
3.1.2 Radioactive reagents 
 
Name (specific activity)    Source (supplier / company) 
[g-32P]ATP (3,000 Ci/mmol)    PerkinElmer Life Sciences 
myo-[3H]Inositol (18 Ci/mmol)   PerkinElmer Life Sciences 
[3H]IP3 (21 Ci/mmol)      PerkinElmer Life Sciences 
Levo-[2,5,6-3H]Noradrenaline (56.4 Ci/mmol) PerkinElmer Life Sciences 
[9,10-3H]Oleic acid (5 Ci/mmol)   PerkinElmer Life Sciences 
L-a-Dipalmitoyl [2-palmitoyl-9,10-3H] 
PtdCho (89 Ci/mmol)     PerkinElmer Life Sciences 
 
3.1.3 Antibodies / Enzymes / Miscellaneous 
 
Name  Source (supplier / company) 
Alexa-488 goat anti-mouse IgG (H+L) conjugate Molecular Probes, MoBiTec 
Alexa-633 goat anti-rabbit IgG (H+L) conjugate Molecular Probes, MoBiTec 
Alkaline phosphatase, shrimp    Roche Molecular Biochemicals 
anti-ARF1 antibody (rabbit) Santa Cruz Biotechnology 
anti-Cdc42 antibody (rabbit)  Santa Cruz Biotechnology 
anti-flag antibody (mouse)    Strategene 
anti-Ga12 (rabbit)     Santa Cruz Biotechnology 
anti-Ga13 (rabbit)     Santa Cruz Biotechnology 
anti-Gaq (rabbit)     Santa Cruz Biotechnology 
anti-HA antibody (mouse)    Dr. J. Bos 
anti-His antibody (mouse)    Santa Cruz Biotechnology 
anti-myc antibody (mouse)    Calbiochem 
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anti-PLD1 antibody (rabbit)    Dr. S. Bourgoin 
anti-PLD2 antibody (rabbit)    Dr. S. Bourgoin 
anti-Rac1 antibody (rabbit)  Santa Cruz Biotechnology 
anti-RGS4 antibody (rabbit)    Dr. T. Wieland 
anti-RhoA antibody (mouse)    Santa Cruz Biotechnology 
anti-Rho-kinase antibody (goat)   Santa Cruz Biotechnology 
DNase I       Roche Molecular Biochemicals 
goat anti-mouse IgG/Peroxidase-conjugate  Dianova 
goat anti-rabbit IgG/Peroxidase-conjugate  Sigma 
Proteinase K      Promega 
Restriction endonucleases    New England Biolabs 
RNase A      Qiagen 
T4 DNA ligase kit     Promega 
Glutathione sepharose beads    Amersham Biosciences 
Ni-NTA superflow suspension beads    Qiagen 
Molecular weight standards    Sigma 
1 Kb DNA ladder      Invitrogen 
Lambda DNA/ EcoRI + HindIII marker  Promega 
 
3.1.4 Plasmids 
 
Name  Supplier 
pAcGHLT 
RhoA       Dr. K. Kaibuchi 
Rho-kinase CAT      Dr. K. Kaibuchi 
ARF1       Dr. B. Lohmann    
PLD1       Drs. A. Morris and M.A. Frohman 
PLD2       Drs. A. Morris and M.A. Frohman 
 
pAdEasy-1 
LacZ       Dr. T. Wieland 
Lsc-RGS      Dr. T. Wieland 
RGS4       Dr. T. Wieland 
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pAdTrack-CMV     Dr. T. Wieland  
 
 
pcDL-SRa  
HA-tagged cofilin     Dr. K. Mizuno 
HA-tagged cofilin (S3A)    Dr. K. Mizuno 
 
pCGN 
PLD1        Dr. M.A. Frohman 
PLD1 (K898R)     Dr. M.A. Frohman 
PLD2         Dr. M.A. Frohman 
PLD2 (K758R)      Dr. M.A. Frohman 
 
pCIS 
Gaq       Dr. T. Wieland 
Ga12       Dr. T. Wieland 
Ga13       Dr. T. Wieland 
Gaq (R183C)      Dr. T. Wieland  
Ga12 (Q229L)      Dr. T. Wieland 
Ga13 (Q226L)      Dr. T. Wieland 
Ga12 (G228A)      Dr. S. Offermanns 
Ga13 (G225A)      Dr. S. Offermanns 
 
pEF 
myc-tagged Rho-kinase    Dr. K. Kaibuchi 
myc-tagged Rho-kinase (amino acids 6-553)  Dr. K. Kaibuchi 
myc-tagged Rho-kinase (amino acids 941-1388) Dr. K. Kaibuchi 
myc-tagged C3 transferase    Dr. A. Hall 
 
pEXV 
myc-tagged Cdc42 (T17N)    Dr. A. Hall 
myc-tagged Rac1 (T17N)    Dr. A. Hall 
 
pQE60 
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His6-tagged cofilin     Dr. K. Mizuno 
His6-tagged cofilin (S3A)    Dr. K. Mizuno 
 
 
pRK5 
ARF1 (T31N)      Dr. B. Lohmann   
ARF1 (Q71L)      Dr. B. Lohmann   
    
pUCD2 
HA-tagged LIM-kinase    Dr. K. Mizuno 
HA-tagged LIM-kinase (T508EE)   Dr. K. Mizuno 
HA-tagged LIM-kinase (D460A)   Dr. K. Mizuno 
 
pUCD2 SRa  
GST/flag-tagged LIM-kinase    Dr. K. Mizuno 
 
pGEX 
GST-tagged Rhotekin-RBD    Dr. S. Offermanns 
 
3.1.5 Bacteria 
 
Strains  Remarks 
DH5a/DH10B  Large-scale production of plasmids  
BJ5183  Homologous recombination of adenovirus 
 
3.1.6 Other materials 
 
Name        Source (supplier / company) 
Agefix Neutol Liquid NE    Agfa Gevaert 
Agefix Fixer      Agfa Gevaert 
Anion exchange AG 1-X8 resin   BIO-RAD 
BCA protein assay reagent    Pierce 
Chromatography paper    Whatman 
Cryo vials      Greiner 
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Electroporation cuvette     BIO-RAD 
Emulsifier scintillator Plus/299    Canberra Packard 
Insulin syringe      Falcon 
Kodak X-OMAT AR-films    Kodak 
Lipofectamine reagent     Promega 
Nitrocellulose membrane    Advanced Microdevices 
Plasmid purification kit     Qiagen 
QIAquick Gel Extraction kit    Qiagen 
Slide-A-Lyzer cassette     Pierce 
Sterile filter (0,20 µm)     Sartorius 
Scintillation vials     Packard 
Silica gel 60C      Merck 
Western LightningTM     PerkinElmer Life Sciences 
 
 
3.2 Methods 
 
3.2.1 Cell culture 
 
3.2.1.1 HEK-293 cells, N1E-115 neuroblastoma cells and PC12 cells 
 
Cell culture was performed in a sterile laminar airflow (Laminar Air HA 2472 GS, 
Heraeus). Medium and solutions were either autoclaved (121°C, 30 min) or sterile filtered (0.2 mm, 
Sartorius). The cells were routinely grown as monolayer in 20 ml DMEM/F12 medium, containing 
10 % (v/v) FCS, 100 U/ml penicillin G and 100 mg/ml streptomycin, on 145-mm culture dishes at 
37°C in an incubator (B5060 EK/CO2, Heraeus) with a humidified, 5 % CO2 atmosphere. For 
experiments, cells were subcultured on 35- or 60-mm culture dishes unil near confluency. For 
storage in liquid nitrogen, cells were centrifuged for 5 min at 1,800 rpm (Megafuge 1.0 R, Heraeus) 
and resuspended in preserving medium (45 % (v/v) DMEM/F12 medium, 45 % (v/v) FCS, 10 % 
(v/v) DMSO). This cell suspension was slowly frozen at -80°C for 24 h before final storage in liquid 
nitrogen. For cell recovery, the cells were quickly thawed at 37°C, centrifuged to remove the 
DMSO-containing medium and seeded in 20 ml DMEM/F12 medium on 145-mm culture dishes. 
HEK-293 wild-type cells transformed by E1 of human adenovirus type 5 (Ad 5) DNA 
were used to generate recombinant PLD adenoviruses. HEK-293 cells, stably expressing the M3 
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mAChR at a density of about 200,000 receptors per cell (Peralta et al., 1988), were maintained in 
the presence of 0.5 mg/ml G418 (neomycin analogue). Experiments with HEK-293 cells were 
performed on 35- or 60-mm culture dishes pretreated with 0.02 mg/ml poly-L-lysine for 10 min to 
improve attachment of the cells. N1E-115 neuroblastoma cells, established by cloning the C-1300 
spontaneous mouse neuroblastoma tumor (Amano et al., 1972), were detached by resuspension in 
Ca2+-free versene (137 mM NaCl, 2.6 mM KCl, 0.54 mM EDTA, 8.4 mM KH2PO4). PC12 cells, 
derived from a transplantable rat pheochromocytoma, were detached by incubation with 0.25 % 
(w/v) trypsin for 1 min (Alemany et al., 2001). 
 
3.2.1.2 Sf9 cells 
 
Sf9 cells were cultured in TNM-FH medium supplemented with 10 % (v/v) FCS, 4.2 mM 
NaHCO3, 100 U/ml penicillin G and 100 mg/ml streptomycin at 27°C (HERAcool 40, Heraeus, 
CO2 supply was not required). For storage in liquid nitrogen, Sf9 cells were centrifuged for 5 min at 
1,800 rpm (Megafuge 1.0 R, Heraeus) and resuspended in preserving medium (45 % (v/v) TNM-
FH medium, 45 % (v/v) FCS, 10 % (v/v) DMSO). This cell suspension was frozen at -80°C for 24 
h and transferred for storage in liquid nitrogen. For cell recovery, the frozen cells were thawed at 
37°C and incubated with 4 ml TNM-FH medium for 60 min in 25-cm2 culture flasks. After 
attachment of the cells, the DMSO-containing medium was removed and the cells were cultured in 
20 ml TNM-FH medium. 
 
3.2.2 Transformation of bacteria 
 
3.2.2.1 Calcium chloride method 
 
A DH5a/DH10B E. coli culture in 20 ml LB medium was transferred into 500 ml LB 
medium and cultured at 37°C with constant shaking (Certomat, Braun) until the OD600 reached ~0.4. 
The bacteria were harvested by centrifugation for 10 min at 5,000 rpm at 4°C (Sorvall RC-5B, 
DuPont), resuspended in ice-cold 150 ml 50 mM CaCl2 and incubated for 5 min on ice. After 
recentrifugation, the bacteria were incubated with ice-cold 8 ml 50 mM CaCl2 for 1 h, before 8 ml 
50 mM CaCl2 containing 40 % (v/v) glycerol were added. The mixture was aliquoted, snap-frozen in 
liquid nitrogen and stored at -80°C. For transformation, 100 ml CaCl2-treated bacteria were mixed 
with an appropriate amount of DNA in a pre-chilled polypropylene tube for 15 min on ice. The 
mixture was incubated for 90 s at 42°C, followed by another 5 min incubation on ice. 300 ml SOC 
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medium was added and the mixture was incubated at 37°C for 30 min. Thereafter, the bacteria were 
plated onto the LB agar plates containing the appropriate antibiotics and incubated at 37°C overnight 
(GTR 0241, Memmert).  
 
LB-ampicillin plates 
 
LB agar  
Ampicillin 
 
32 
100 
 
mg/ml 
mg/ml 
          
LB-kanamycin plates 
 
 
LB-streptomycin plates 
LB agar  
Kanamycin 
 
LB agar 
Streptomycin 
 
32 
     30 
 
32 
30 
mg/ml 
mg/ml 
 
mg/ml 
mg/ml 
3.2.2.2 Electroporation method 
 
A DH10B/BJ5183 E. coli culture in 100 ml LB medium was diluted in 1000 ml LB 
medium and cultivated at 37°C, until OD600 reached ~0.8. The bacteria were harvested by 
centrifugation (see above) and incubated on ice for 1 h. They were washed twice with 100 ml ice-
cold 10 % (v/v) glycerol. Finally, the bacteria were resuspended in 5 ml ice-cold 10 % (v/v) 
glycerol, aliquoted, snap-frozen in liquid nitrogen and stored at -80°C.  
40 ml electrocompetent DH10B/BJ5183 E. coli were mixed with 50 - 300 ng DNA in a 
pre-chilled polypropylene tube and transferred into an ice-prechilled cuvette, which was pretreated 
for 15 min under UV. Electroporation was performed in a Gene Pulser electroporator (200 Ohm / 
25 µF / 2.5 KV; BIO-RAD). Afterwards, 1 ml SOC medium was added, and the bacteria were 
incubated at 37°C for 1 h. Finally, transformed bacteria were plated onto agarose plates containing 
appropriate antibiotics and incubated at 37°C overnight (GTR 0241, Memmert).  
 
3.2.3 Transfection of cells 
   
3.2.3.1 Calcium phosphate method 
 
Subconfluent cell monolayers grown on 145-mm culture dishes were fed with fresh 
DMEM/F12 medium one day before transfection. Appropriate amounts of cDNAs were transferred 
into reaction tubes (Eppendorf 1,5 ml) and adjusted with H2O to 80 ml. The cDNAs were 
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precipitated by addition of 20 ml 3 M sodium acetate (pH 5.2) and 250 ml ethanol. The mixture was 
centrifuged for 10 min at 13,000 rpm (Biofuge 13, Heraeus). The DNA pellets were air-dried at RT 
and resuspended in 700 ml H2O. Thereafter, DNA solutions were thoroughly mixed with 300 ml 2 M 
CaCl2 and 1 ml 2 ´ HeBS solution and incubated for 10 min. 200 ml 10 mM chloroquine were 
added to the cell monolayers to reduce the degradation of cDNA by lysosomal hydrolases. The 
cDNA/CaCl2/HeBS-mixture was carefully transferred onto the chloroquine-pretreated cell 
monolayer, and the cells were placed for 4 - 5 h in an incubator (B5060 EK/CO2, Heraeus). 
Afterwards, the cell monolayers were washed once with FCS-free DMEM/F12 medium and then 
cultured in fresh DMEM-F12 medium. After 24 h, the cells were splitted on appropriate dishes and 
used for experiments 48 – 72 h after transfection. The transfection efficiency was 50 - 70 %. 
To examine protein expression, cells on 35- or 60-mm culture dishes were washed twice 
with HBSS and scraped into ~0.3 ml lysis buffer (10 mM Tris/HCl, 1 % (m/v) SDS, pH 7.4). The 
lysates were incubated for 10 min at 95°C (Thermoblock, Eppendorf). After protein determination 
by the Pierce method, 75 - 100 mg protein of the samples were loaded onto polyacrylamide gels, 
and protein expression was analyzed by immunoblotting with appropriate antibodies. 
 
2 ´ HeBS, pH 7.05 NaCl 
HEPES 
Na2HPO4 
   280 
50 
  1.48 
 
mM 
mM 
mM 
 
3.2.3.2 Lipofectamine method 
 
cDNA was incubated with 20 ml lipofectamine reagent in 1 ml FCS-free DMEM/F12 
medium for 15 min at RT. Cell monolayers (70 - 80 % confluent) on 145-mm culture dishes were 
washed twice with FCS-free DMEM/F12 medium. Thereafter, the DNA-lipid mixture was 
transferred to the cell monolayers with 4 ml DMEM/F12 medium, and the cells were incubated for 4 
h (B5060 EK/CO2, Heraeus). Finally, the cells were washed two times with FCS-free DMEM/F12 
medium and cultivated in DMEM-F12 medium. 
 
3.2.4 Membrane preparation  (Schmidt et al., 1996c) 
 
All steps were performed at 4°C. Cells were harvested, washed with 50 ml HP buffer and 
resuspended in 60 ml buffer B. The cell suspension (~2 x 107 cells/ml) was subjected to nitrogen 
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cavitation at 500 p.s.i. for 30 min on ice. Thereafter, the EGTA concentration of the cavitate was 
adjusted to 1.25 mM, followed by centrifugation for 10 min at 2,400 rpm (Megafuge 1.0R, 
Heraeus) to pellet nuclei and unbroken cells. The supernatant was filtered through a two-layer gauze 
filter to remove light lipid debris and centrifuged for 20 min at 20,000 rpm (Sorvall RC-5B, DuPont). 
The precipitated membrane fraction was washed in buffer E and stored in aliquots (~20 mg/ml in 
buffer E) in liquid nitrogen.  
 
HP buffer, pH 7.4 Triethanolamine/HCl 
NaCl 
     10 
   140 
 
mM 
mM 
 
Buffer B, pH 7.5 Tris/HCl  
Sucrose 
MgCl2 
ATP 
Benzamidine 
Leupeptin 
PMSF 
Soybean trypsin inhibitor 
 
     20 
   250 
    1.5 
       1 
       3 
       1 
       1 
       2 
        
mM 
mM 
mM 
mM 
mM 
mM 
mM 
mg/ml 
Buffer E, pH 7.5  Tris/HCl 
EDTA 
DTT 
Benzamidine 
Leupeptin 
PMSF 
Soybean trypsin inhibitor 
 
     20 
       1 
       1 
       3 
       1 
       1 
       2 
       
mM 
mM 
mM 
mM 
mM 
mM 
mg/ml 
 
3.2.5 Purification of recombinant proteins 
 
3.2.5.1 Sf9 cells  
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To obtain GST-tagged fusion proteins of RhoA, ARF1, Rho-kinase CAT, PLD1 and 
PLD2, Sf9 cells were infected with the appropriate recombinant baculoviruses. For that, 1 ml virus 
stock and 4 ml TNM-FH medium were added to the cell monolayer (~5 MOI) and incubated at 
27°C for ~3 h. Afterwards, 20 ml TNM-FH medium were added, and the cells were cultured for at 
least 3 days. 
The cells were harvested, centrifuged for 15 min at 1,800 rpm at RT (Sorvall RC-5B, 
DuPont), washed once with ice-cold Ca2+/Mg2+-free PBS and resuspended in TegD buffer I. The 
cells were disrupted by sonification (4 ´ 30 s, 4°C, Labsonic U, Braun) and centrifuged for 1 h at 
20,000 rpm at 4°C (Sorvall RC-5B, DuPont). The supernatant containing the GST-tagged proteins 
was mixed with glutathione Sepharose beads, which were equilibrated with 2 ´ 5 ml TegD buffer II. 
The mixture was incubated for 2 h at 4°C under gentle rocking (REAX 2, Heidolph). Finally, the 
beads were washed twice with appropriate buffer and stored at 4°C for experiments. 
Alternatively, for purification of Rho-kinase CAT, RhoA, and ARF1, glutathione 
Sepharose beads were filled into a chromatography column (BIO-RAD) and equilibrated with TegD 
buffer II. The supernatant was loaded on the column at 4°C. Thereafter, the column was washed 
with 30 ml TegD buffer II, and the bound recombinant protein was eluted with 1 ml TegD buffer III. 
The protein concentration (either bound on beads or soluble) was determined by the Bradford 
method. Preparations were analyzed for homogeneity by SDS-PAGE and Coomassie-blue staining. 
The GST-tagged proteins were identified by immunoblotting with appropriate antibodies. 
 
TEgD buffer I, pH 7.5  
 
 
 
 
 
Tris/HCl  
EGTA 
DTT 
Sucrose 
PMSF 
Leupeptin 
 
     50 
       2 
       1 
   250 
     10 
       1 
 
mM 
mM 
mM 
mM 
mM  
mg/ml 
TEgD buffer II, pH 7.5  
 
 
Tris/HCl 
EGTA 
DTT 
     50 
       2 
       1 
 
mM 
mM 
mM 
 
TEgD buffer III, pH 7.5  
 
Tris/HCl  
EGTA 
     50 
       2 
mM 
mM 
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PBS, pH 7.2 
 
DTT 
Reduced glutathione 
 
NaCl 
KCl 
Na2HPO4 
KH2PO4 
CaCl2 
MgCl2 
       1 
     10 
 
137 
2.7 
6.5 
1.5 
0.9 
0.5 
 
mM 
mM 
 
mM 
mM 
mM 
mM 
mM 
mM 
3.2.5.2 E. coli 
 
His6-tagged cofilin and GST-tagged Rho-binding domain (RBD) of Rhotekin (amino acids 
7-89, Ren & Schwartz, 2000) were expressed in E. coli. The selected colony grown on a LB-agar 
plate was inoculated in 100 ml LB medium containing 100 mg/ml ampicillin and incubated overnight 
at 37°C. The culture was diluted in 1000 ml LB medium containing 100 mg/ml ampicillin and further 
incubated at 37°C until its OD600 reached ~0.4. Then, IPTG was added up to a final concentration 
of 0.5 mM to induce the expression of recombinant proteins. After additional incubation for 3 h at 
37°C, the bacteria were centrifuged for 15 min at 6,500 rpm at 4°C (Sorvall RC-5B, DuPont) and 
resuspended in 35 ml buffer A for His6-tagged cofilin or 40 ml PBS supplemented with proteinase 
inhibitors for GST-tagged RBD. The bacteria were disrupted by sonification (4 ´ 30 s, 4°C, 
Labsonic U, Braun) and Triton X-100 was added up to a final concentration of 1 % (v/v). The 
mixture was incubated for 30 min at 4°C with gentle shaking (REAX 2, Heidolph) and centrifuged 
for 15 min at 18,000 rpm at 4°C (Sorvall RC-5B, DuPont). The supernatant was incubated 
overnight with either Ni-NTA superflow suspension beads for His6-tagged cofilin or glutathione 
Sepharose beads for GST-tagged RBD at 4°C while gently rocking (REAX 2, Heidolph). 
The glutathione Sepharose beads with GST-tagged RBD were washed with appropriate 
buffer and stored at 4°C. The Ni-NTA beads with His6-tagged cofilin were packed in a 
chromatography column (BIO-RAD) and washed three times with 20 ml buffer B to remove 
nonspecifically bound proteins. Cofilin was eluted by addition of 5 ´ 1 ml buffer C. The eluate was 
consecutively dialyzed overnight and 2 ´ 2 h against 500 ml buffer A at 4°C. Finally, cofilin was 
concentrated (microconcentrator, Centricon 10) by centrifugation for 30 min at 6,000 rpm at 4°C 
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(Sorvall RC-5B, DuPont). The protein concentration was determined by the Bradford method. The 
concentrated eluate was analyzed by SDS-PAGE and cofilin visualized by Coomassie-blue staining.  
 
Buffer A, pH 8.0 Tris/HCl 
NaCl 
MgCl2 
2-Mercaptoethanol 
Glycerol 
 
     50 
   100 
       2 
       6 
5 % 
 
mM 
mM 
mM 
mM 
v/v 
 
Buffer B, pH 8.0 
 
 
Buffer C, pH 8.0 
Buffer A plus  
Imidazole 
 
Buffer A plus 
Imidazole 
 
     
25 
 
 
400 
 
 
mM 
 
 
mM 
PBS (supplemented)  PBS (without Ca2+, Mg2+) 
DTT 
PMSF 
Leupeptin 
Benzamidine 
Aprotinin  
Soybean trypsin inhibitor 
 
    0.5 
       1 
       1 
       1 
    0.1 
       2 
 
mM 
mM 
mg/ml 
mg/ml 
mM 
mg/ml 
 
 
3.2.5.3 TSA cells 
 
TSA cells are HEK-293 cells transformed with temperature-sensitive tsA SV-40 virus and 
stably expressing the large SV40 T antigen. To obtain recombinant LIM-kinase, subconfluent TSA 
cells were transfected by the calcium phosphate method with pUCD2 SRa GST/flag-tagged LIM-
kinase. The transfected cells were harvested by centrifugation for 15 min at 1,800 rpm at RT 
(Sorvall RC-5B, DuPont), washed once with ice-cold Ca2+/Mg2+-free PBS and resuspended in 
TegD buffer I. Purification of LIM-kinase was performed as described in 3.2.5.1. 
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3.2.6 Protein determination 
 
3.2.6.1 Bradford method (Bradford, 1976) 
 
Protein samples were appropriately diluted, adjusted to 800 ml with H2O (800 ml H2O was 
used as reference value) and thoroughly mixed with 200 ml Bradford reagent in a disposable 
Polystryrol cuvette. The samples were measured at OD595 nm (LKB Biochrom Ultraspec II 
spectrometer, Pharmacia) after they had reacted for 10 min. Protein concentrations were calculated 
against a standard curve ranging from 0.4 - 2.0 mg/ml calf g-globulin. 
 
Bradford reagent Serva-blue G 
Ethanol 
Phosphoric acid (85 %) 
   350 
 25 % 
 25 % 
 
mg/ml 
(v/v) 
(v/v) 
 
 
3.2.6.2 Pierce method (Smith et al., 1985) 
 
To determine the protein concentration of samples in SDS-containing lysis buffer, the 
standard BCA Protein Assay kit (Pierce) was used as indicated. Protein concentration was 
measured at OD562 nm (LKB Biochrom Ultraspec II spectrometer, Pharmacia).  
 
3.2.7 SDS-PAGE and immunoblotting (Laemmli, 1970; Towbin et al., 1979) 
 
For production of polyacrylamide gels, acrylamide and bis-acrylamide were mixed in a 
proportion of 30:0.8, and the polymerization was initiated by addition of TEMED and ammonium 
peroxodisulfate. The stacking gel contained 6 % (m/v) acrylamide, while acrylamide concentration 
(10 %, 12.5 %, 15 % (m/v)) of the separating gel was dependent on molecular size of the proteins of 
interest. Samples were incubated in Laemmli sample buffer for 10 min at 95°C before loading onto 
the gel. Electrophoresis was performed at 36 mA for 4 h in electrophoresis buffer. 
For immunoblotting, the separated proteins on the gel were transferred onto nitrocellulose 
membranes by electrophoresis (100 mA) overnight at 4°C in blot buffer. The membranes were 
stained with Ponceau S. To eliminate unspecific binding, the membranes were blocked for 2 h with 
TBS containing 5 % (w/v) skim milk powder. After short rinse with TBS, the membranes were 
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incubated for at least 1 h with appropriate primary antibodies, which were diluted in TBS containing 
0.1 % (m/v) BSA. The membranes were then rinsed three times with TBS containing 0.2 % (m/v) 
Tween 20, followed by 10 min blot in TBS containing 5 % (w/v) skim milk powder. Afterwards, the 
membranes were incubated for 1 h with the suitable peroxidase-conjugated secondary antibodies 
(dilution 1:5,000 to 1:10,000). The membranes were rinsed three times with TBS containing 0.2 % 
(m/v) Tween 20, then incubated for 1 min with ECL reagent. The chemiluminescent reaction was 
detected on Kodak X-ray films by exposure for 30 s - 20 min.  
Alternatively, the separated proteins on the gel were directly stained with Coomassie-blue 
staining solution. The gels were vacuum dried at 80°C (Gel Dryer 543, BIO-RAD). 
 
2 ´ Separating buffer, pH 8.8 
 
 
2 ´ Stacking buffer, pH 6.8 
Tris/HCl 
SDS 
 
Tris/HCl 
SDS 
 
    750 
  0.2 % 
 
    250 
  0.2 % 
 
mM 
(m/v) 
 
mM 
(m/v) 
Laemmli sample buffer, pH 7.5 
(3 ´ concentrated)  
Tris/HCl 
SDS 
2-Mercaptoethanol 
Glycerol 
Bromphenol blue dye 
 
     20 
 6.6 % 
  20 % 
  33 % 
 0.1 %  
mM 
(m/v) 
(v/v) 
(v/v) 
(m/v) 
Electrophoresis buffer, pH 8.3 Tris 
Glycine 
SDS 
 
      25 
    200 
     1 % 
mM 
mM 
(m/v) 
Blot buffer, pH 8.3 Tris/HCl 
Glycine 
SDS 
Methanol 
 
      40 
    300 
0.01 % 
   20 % 
mM 
mM 
(m/v) 
(v/v) 
TBS, pH 7.4  
 
Tris/HCl 
NaCl 
      10 
    150 
mM 
mM 
3. Materials and Methods 
 
 38
 
Coomassie-blue staining solution Serva blue R 
Methanol 
Acetic acid 
 
1.4      
50 % 
   10 % 
mg/ml 
(v/v) 
(v/v) 
Ponceau S Ponceau S 
Acetic acid 
  0.1 % 
     5 % 
(m/v) 
(v/v) 
 
High molecular weight standards 
 
 
 
 
Myosin 
b-Galactosidase 
Phosphorylase b 
Albumin, bovine 
Albumin, egg 
Carbonic anhydrase 
 
205 
116 
97.4 
66 
45 
29 
kDa 
kDa 
kDa 
kDa 
kDa 
kDa 
 
Low molecular weight standards 
 
 
 
 
Albumin, bovine 
Albumin, egg 
Glyceraldehyde-3-
phosphate-dehydrogenase 
Carbonic anhydrase 
Trypsinogen 
Soybean trypsin inhibitor 
a-Lactalbumin 
66 
45 
36 
 
29 
24 
20 
14.2 
kDa 
kDa 
kDa 
 
kDa 
kDa 
kDa 
kDa 
 
3.2.8 Interaction of PLD and cofilin 
 
Glutathione Sepharose beads loaded with GST-PLD1 or GST-PLD2 were rinsed with 
TEgD buffer II (see 3.2.5.1) and equally divided in 1.5 ml Eppendorf tubes (10 - 30 mg protein per 
tube). The beads were incubated overnight with 30 mg recombinant cofilin (wild type or S3A) or 
with buffer A (see 3.2.5.2) at 4°C with gentle shaking (REAX 2, Heidolph). The beads were 
collected by centrifugation (2 min, 4°C, 1800 rpm) and washed three times with 700 ml ice-cold 
buffer A to remove unspecifically bound proteins. Finally, the beads were resuspended in Laemmli 
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sample buffer. PLD and cofilin were separated by SDS-PAGE and detected by immunoblotting (see 
3.2.7.) with anti-PLD and anti-His antibodies, respectively. 
 
3.2.9 Phosphorylation of recombinant proteins 
 
To study whether LIM-kinase phosphorylates PLD1 in vitro, GST-LIM-kinase-bound 
glutathione Sepharose beads (15 - 25 mg protein) were equilibrated with P-buffer and mixed with 20 
- 25 mg recombinant PLD1 or membranes of PLD1-overexpressing Sf9 cells in the presence and 
absence of recombinant ARF1, Rho-kinase CAT or cofilin. Alternatively, 10 - 30 ml eluted LIM-
kinase in TEgD buffer III was used (see 3.2.5.1). The mixtures were preincubated for 5 min at 
37°C and ATP-mix was added at a dilution of 1:5 to start the phosphorylation reaction. After 15 
min, the reaction was stopped by addition of Laemmli sample buffer and heating for 5 min at 95°C. 
The proteins were separated by SDS-PAGE, and phosphorylated proteins detected by 
autoradiography using Kodak X-Omat AR films. Phosphorylation of cofilin by LIM-kinase was 
typically performed for 45 min at 25°C. 
 
P-buffer, pH 7.4 MgCl2 
EDTA 
EGTA 
DTT 
Tris/HCl 
       5 
       1 
    0.1 
       1 
     25 
mM 
mM 
mM 
mM 
mM 
 
ATP-mix, pH 7.5  MgCl2 
CaCl2 
MgATP 
[g-32P]ATP 
Tris/HCl 
 
     25 
       1 
   250 
       5 
   100 
mM 
mM 
mM 
mCi/sample 
mM 
 
3.2.10 Immunofluorescence laser confocal microscopy 
 
HEK-293 cells, stably expressing the M3 mAChR, were transiently transfected with  PLD 
and/or cofilin and grown on coverslips (Falcon) pretreated with 0.1 mg/ml poly-D-lysine. The cells  
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were rinsed with Moscona and incubated with agonists dissolved in Moscona for 15 min at 37°C. 
Thereafter, the cells were fixed and permeabilized with ethanol/acetone (1/1, v/v) for 10 min at RT, 
followed by two washes with Moscona. The unspecific binding sites of the cells were blocked for 15 
min by incubation with Moscona/BSA (Moscona supplemented with 0.5 % BSA). The cells were 
rinsed, incubated with the primary antibodies (anti-PLD or anti-His) diluted in Moscona/BSA. 
Afterwards, the cells were rinsed three times with Moscona/BSA, incubated for 45 min in darkness 
with the corresponding fluorescence-conjugated secondary antibodies (Alexa-633 red for PLD, 
Alexa-488 green for cofilin) at RT. The secondary antibodies were washed out in darkness with 
Moscona/BSA, and the cell specimens were mounted in Moscona supplemented with 90 % (v/v) 
glycerol and 1.0 % (v/v) p-phenylenediamine. Confocal immunofluorescence imaging was performed 
using Zeiss LSM 510 Axiovert 100M confocal laser scanning microscopy system (Plan-Neofluor 
40´/1.3 oil objective, 488 nm / 633 nm excitation).  
 
Moscona buffer, pH 7.4 
 
NaCl 
D(+)-Glucose 
NaHCO3 
KCl 
NaH2PO4 
KH2PO4 
  13.6 
     10 
     12 
       4 
  0.36 
  0.18 
 
mM 
mM 
mM 
mM 
mM 
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3.2.11 Phalloidin staining and fluorescence microscopy 
 
Cell monolayers on coverslips (as described above) were rinsed with Moscona and fixed 
with 3 % (v/v) para-formaldehyde for 15 min, followed by two washes with Moscona. Cells were 
permeabilized by incubation with 0.05 % (v/v) Triton X-100. The cells were washed three times with 
Moscona and then incubated for 15 min with TRITC-phalloidin (25 mg/ml) to stain the actin 
filaments. After washout of TRITC-phalloidin, the cells were mounted with Moviol (Calbiochem) 
and examined by fluorescence microscopy (Zeiss Axiovert S100, 546 nm excitation). 
 
3.2.12 Subcellular translocation of ARF1 and RhoA (Heneweer et al., 2002) 
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To determine the subcellular distribution of ARF1 and RhoA, cell monolayers were 
detached, the cells were washed with PBS and resuspended in PBS at a concentration of ~4 ´ 107 
cells/ml. 40 ml aliquots were incubated with receptor agonists for 10 min at 37°C. 950 ml lysis buffer 
A were added, and the cells were lysed by three freeze/thaw cycles (snap-freezing in liquid nitrogen 
followed by thawing at 37°C). The lysates were centrifuged for 10 min at 10,000 rpm at 4°C 
(Biofuge 13, Heraeus). The pellets were resuspended in 500 ml lysis buffer B, sonified for 10 s at 
4°C (Labsonic U, Braun) and again centrifuged for 10 min at 10,000 rpm at 4°C (Biofuge 13, 
Heraeus). The content of ARF1/RhoA in the supernatant was determined by SDS-PAGE and 
immunoblotting with appropriate antibodies.  
 
Lysis buffer A, pH 7.4 EDTA 
EGTA 
DTT 
Tris/HCl 
PMSF 
Leupeptin 
Aprotinin 
Soybean trypsin inhibitor 
 
       2 
       2 
       1 
     20 
       1 
     10 
       2 
     50 
 
mM 
mM 
mM 
mM 
mM 
mM 
mg/ml 
mg/ml 
 
Lysis buffer B, pH 7.4 Lysis buffer A plus 
Triton X-100 
 
    1 % 
 
(v/v) 
 
3.2.13 "Pull-down" assay of RhoA (Ren & Schwartz, 2000) 
 
Alternatively, RhoA activation was assessed by measuring the binding of RhoA to GST-
tagged RBD of Rhotekin. Subconfluent cell monolayers were rinsed with HBSS and incubated with 
agonists for 2 - 5 min at 37°C. The stimulation was stopped by addition of ice-cold 700 ml GST-fish 
buffer. The cells were scraped, incubated for 10 min on ice in 1.5 ml Eppendorf tubes and then 
centrifuged for 10 min at 10,000 rpm at 4°C (Biofuge 13, Heraeus). The RhoA-containing 
supernatant was incubated for 2 h with the GST-tagged RBD-bound glutathione Sepharose beads 
(30 mg protein pro sample) at 4°C with gentle shaking (REAX 2, Heidolph). Thereafter, the beads 
were spun down, washed twice with 1 ml GST-fish buffer and resuspended in Laemmli sample 
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buffer for SDS-PAGE. The presence of RhoA was detected by immunoblotting with the anti-RhoA 
antibody. 
 
HBSS, pH 7.4 
 
NaCl 
D(+)-Glucose 
KCl 
CaCl2 
MgCl2 
HEPES 
   118 
       5 
       5 
       1 
       1 
15 
 
mM 
mM 
mM 
mM 
mM 
mM 
GST-fish buffer Tris/HCl 
NaCl 
MgCl2 
PMSF 
Glycerol 
Nonidet P-40 
Leupeptin 
Aprotinin 
Soybean trypsin inhibitor 
50 
100 
2 
1 
10 % 
1 % 
1 
100 
10 
mM 
mM 
mM 
mM 
(v/v) 
(v/v) 
mg/ml 
nM 
mg/ml 
 
3.2.14 Assay of PLD activity in intact cells (Schmidt et al. 1999) 
 
In the presence of ethanol, PLD catalyzes the transphosphatidylation of its substrate 
phosphatidylcholine (PtdCho) to produce the metabolically stable phosphatidylethanol (PtdEtOH) 
(Exton, 2002). Cells were replated 24 h after transfection on 35-mm culture dishes, and cellular 
phospholipids were labeled by incubating monolayers for 20-24 h with [3H]oleic acid (2 mCi/ml) in 
culture medium. The cell monolayers were rinsed with HBSS and incubated with agonists/inhibitors 
in HBSS containing 2 % (v/v) ethanol at 37°C. The reactions were stopped by addition of 500 ml 
ice-cold methanol. Cell monolayers were scraped and washed with another 500 ml methanol and 
transferred into 6.5 ml reaction tubes. Cell suspensions were vigorously mixed with 1 ml chloroform 
and 0.5 ml H2O, and the mixtures were centrifuged for 10 min at 3,400 rpm at 4°C (Megafuge 
1.0R, Heraeus). Thereafter, the lower organic phase was transferred into 3.5 ml reaction tubes and 
vacuum dried (Speed Vac plus SC 110A, Savant). Dried lipids were resuspended in 25 ml 
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chloroform/methanol (1/1, v/v), and 10 ml samples were spotted onto thin layer plates (Silica gel 
60C) preloaded with lipid standards (PA and PtdEtOH). Chromatography was performed in 
ethylacetate/iso-octane/acetic acid/H2O (13/2/3/10, v/v/v/v). Afterwards, the separated lipids on the 
plates were stained in an iodine chamber, and the positions were marked according to the standards. 
Radioactive fractions were scraped out and mixed with 3 ml scintillation solution for liquid scintillation 
counting (Beckman LS6000 SC). Measurements in the absence of ethanol were used to determine 
unspecific radioactivity. The formation of [3H]PtdEtOH was expressed as percentage of the total 
amount of labeled phospholipids. 
Alternatively, cells were replated on 145-mm culture dishes and incubated for 20 - 24 h 
with [3H]oleic acid (2 mCi/ml) in culture medium. Thereafter, the cells were detached from the 
dishes, washed twice in HBSS with centrifugation at 1,700 rpm for 5 min at 4°C and resuspended at 
1 ´ 107 cells/ml. Reaction mixtures (200 ml) containing 100 ml cell suspension, 2 % (v/v) ethanol and 
the indicated agonists or inhibitors were incubated for 45 min at 37°C. The reaction was stopped by 
addition of 1 ml ice-cold chloroform/methanol (1/1, v/v) and 0.5 ml H2O. After vortexing, the 
samples were centrifuged for 10 min at 3,400 rpm at 4°C. The lower organic phase was transferred 
into 3.5 ml reaction tubes, and the samples were further processed as described above.  
 
3.2.15 PLD activity measurement in vitro 
 
[3H]PtdCho and PIP2 in a molar ratio of 10:1 were vacuum dried (Speed Vac plus SC 
110A, Savant) and emulsified in vesicle solution by sonication (3 ´ 20 s; Labsonic U, Braun). The 
lipids (200 mM [3H]PtdCho, 500,000 cpm per assay; 25 mM PIP2) were mixed with membrane 
fractions (200 mg protein), 2 % (v/v) ethanol, agonists and regulatory factors in 100 ml assay buffer. 
The mixture was incubated for 15 min at 30°C for PLD measurement. The reaction was stopped by 
addition of 1 ml ice-cold chloroform/methanol (1/1, v/v) and 0.5 ml H2O. The further procedure was 
as decribed in 3.2.14. The PLD activity was expressed as the formation of PtdEtOH in nmol ´ min-1 
´ mg-1 protein.   
Alternatively, to study the role of phosphorylated cofilin on PLD activity, GST-tagged 
LIM-kinase-bound glutathione Sepharose beads and His6-tagged cofilin (wild type or S3A) were 
incubated together at an appropriate ratio of protein content in the presence or absence of 1 mM 
MgATP for 45 min at 25°C. The GST-tagged LIM-kinase-bound glutathione Sepharose beads 
were removed by centrifugation for 3 min at 2,400 rpm at 4 °C. The supernatant containing 
phosphorylated or non-phosphorylated cofilin was incubated with GST-tagged PLD1/PLD2-bound 
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glutathione Sepharose beads (20 - 30 mg / reaction tube), [3H]PtdCho/PIP2 vesicles, 2 % (v/v) 
ethanol and stimulatory agents for 30 min at 30 °C. The reactions were stopped, and further 
procedures were as described above. 
 
 
Vesicle solution, pH 7.5 
 
 
EGTA 
KCl 
DTT 
HEPES 
 
       3 
     80 
       1 
     50 
 
mM 
mM 
mM 
mM 
 
Assay buffer, pH 7.5  EGTA 
KCl 
MgCl2 
CaCl2 
DTT 
HEPES 
       3 
     80 
       3 
       2 
       1 
     50 
 
mM 
mM 
mM 
mM 
mM 
mM 
 
3.2.16 Inositol phosphate formation assay (Schmidt et al., 2000) 
 
Cells were labeled with myo-[3H]inositol (1 mCi/ml) in inositol-free DMEM/F12 medium 
for 16 - 24 h and equilibrated with HBSS/LiCl (HBSS supplemented with 10 mM LiCl) for 10 min 
at 37°C in 35-mm dishes before challenge with agonists/inhibitors in HBSS/LiCl for 30 min. LiCl 
was included to inhibit the dephosphorylation of myo-[3H]inositol monophosphate (Berridge et al., 
1993). The reaction was stopped by addition of 1 ml ice-cold methanol to the cell monolayers. The 
cells were scraped on ice and transferred into 3.5 ml reaction tubes. Thereafter, 1 ml chloroform and 
0.5 ml H2O were added, and the mixture was vortexed and centrifuged at 3,500 rpm for 10 min at 
4°C (Megafuge 1.0R, Heraeus). The aqueous upper phase was loaded onto an anion exchange resin 
column (AG 1-X8, 200-400 mesh, chloride form) to determine the formation of inositol phosphates. 
The columns were washed with 6 ml H2O and 5 ml 50 mM ammonium formiate containing 0.1 M 
formic acid. Finally, myo-[3H]IPx (= [3H]IP + [3H]IP2 + [3H]IP3) were eluted by addition of 6 ml 1 
M ammonium formiate containing 0.1 M formic acid. Alternatively, measurement of PLC activity 
was performed in cell suspension (see 3.2.14). The upper hydrophilic phase was transferred into 3.5 
ml reaction tubes, and the samples were further handled as described above. The radioactivity was 
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measured in 1 ml aliquots by liquid scintillation spectrometry (Beckman LS6000 SC). Unlabeled 
cells were scraped in 500 ml 0.1 M NaOH for protein determination by the Braford method. [3H]IPx 
formation was expressed as cpm ´ 10-3 ´ mg-1 protein or as cpm ´ 10-3 ´ 10-6 cells. 
 
3.2.17 IP3 and PIP2 mass assays (Schmidt et al., 2000) 
 
For direct measurement of the cellular mass of IP3 and PIP2, transfected cell monolayers on 
35-mm culture dishes (~80 % confluence) were incubated for 1 min with agonists in HBSS. After 
aspiration of the HBSS, 0.5 ml 0.5 M cold TCA was added and allowed to extract the cellular IP3 
for 20 min on ice. The TCA solution was transferred into 6.5 ml reaction tubes and extracted 3 times 
with 3 vol. H2O/diethylether (1/2, v/v) to remove the TCA. 200 ml of the IP3-containing aqueous 
lower phase was transferred to 1.5 ml Eppendorf tubes and mixed with 50 ml 30 mM EDTA (pH 
7.0) and 50 ml 60 mM NaHCO3. 
After TCA extraction, the remaining cell monolayers were analyzed for PIP2 mass. For this, 
0.94 ml cold acidified chloroform/methanol (chloroform/methanol/12 N HCl, 40/80/1, v/v/v) were 
added to the cells, and the cells were immediately scraped, transferred into 6.5 ml reaction tubes and 
mixed with 0.31 ml chloroform and 0.56 ml 0.1 M HCl. After centrifugation for 10 min at 2,400 rpm 
at 4°C (Megafuge 1.0R, Heraeus), 400 ml of the lower phase was transferred to 1.5 ml Eppendorf 
tubes and vacuum dried (Speed Vac, plus SC 110A, Savant). PIP2 was chemically hydrolyzed into 
IP3 by incubation with 0.25 ml 1 M KOH for 15 min at 95°C (Thermoshaker, Schutron). For 
neutralization, KOH-treated samples were loaded onto ion exchange columns (AG 50-X8, 200-400 
mesh, hydrogen form) and eluted with 5 ´ 0.25 ml H2O. The eluate was adjusted to ~pH 7 with 1 
M NaHCO3 and thoroughly mixed with 2 ml 1-butanol/light petroleum ether (5/1, v/v). The mixture 
was centrifuged for 10 min at 2,400 rpm at 4°C (Megafuge 1.0R, Heraeus), and 1 ml of the aqueous 
lower phase was used for the IP3 receptor binding assay. The columns were regenerated by 5 ml 1 
M HCl and 5 ´ 5 ml H2O. 
IP3-binding protein was obtained from bovine adrenal cortex. For this, adrenal cortex 
tissue was thoroughly homogenized (Ultra-Turrax, setting 5-6, Janke & Kunkel) in buffer (20 mM 
NaHCO3, 1 mM dithiothreitol, pH 8.0) and centrifuged at 5,000 rpm for 10 min at 4°C (Megafuge 
1.0R, Heraeus). The supernatant was collected, and the pellet was resuspended in buffer for 
renewed homogenization and centrifugation. The resulting supernatants were combined and 
centrifuged at 15,000 rpm for 20 min at 4°C (Sorvall RC-5B, DuPont). The supernatant was 
discarded, and the pellet was resuspended in 50 ml homogenization buffer and recentrifuged for 20 
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min at 15,000 rpm at 4°C. The pellet was washed two times, adjusted to 15 mg/ml and stored at -
80°C. 
The IP3 receptor binding assay included 30 ml standard IP3 (0.036 - 36 pmol) or the 
unknown samples, 30 ml assay buffer (100 mM Tris/HCl, 4 mM EDTA, pH 8.0), 30 ml [3H]IP3 
(5,000 cpm) and 30 ml IP3-binding protein. Steady-state receptor occupation was allowed to be 
established for 30 min on ice. Thereafter, the mixtures were filtrated on GF/C-filter, and the filters 
were washed 3 times with 3 ml buffer (25 mM Tris/HCl, 1 mM EDTA, 5 mM NaHCO3, pH 8.0). 
Bound [3H]IP3 was determined by liquid scintillation counting. The cellular content of IP3 and PIP2 
was calculated and expressed as pmol ´ mg-1 protein. 
 
3.2.18 Noradrenaline release 
 
PC12 cells in 35-mm dishes were loaded for 40 min at 37°C with 0.1 mCi/ml 
[3H]noradrenaline in HBSS containing 0.2 % fatty acid-free BSA. After washing two times with 
Ca2+/Mg2+-free PBS, the cell monolayers were challenged with 1 ml 30 mM KCl/HBSS or HBSS 
containing 10 mM bradykinin for 10 min at 37°C. The supernatant containing released 
[3H]noradrenaline was directly transferred in a scintillation vial for radioactivity measurement. To 
determine the total cellular content of [3H]noradrenaline, cells were lysed in 1 % (m/v) SDS, 
followed by liquid scintillation counting. 
 
30 mM KCl/ HBSS, pH 7.4 
 
NaCl 
D(+)-Glucose 
KCl 
CaCl2 
MgCl2 
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     93 
       5 
     30 
       1 
       1 
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mM 
mM 
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3.2.19 Generation of recombinant PLD adenoviruses (He et al., 1998) 
  
3.2.19.1 Cloning of PLD into pAdTrack-CMV  
 
To produce recombinant PLD adenovirus, the PLD genes were first excised from the 
eukaryotic expression vector pCGN and cloned into the pAdTrack-CMV shuttle vector, encoding 
green fluorescent protein (GFP; see also Fig. 5). 7.5 - 10 mg pCGN plasmid encoding hPLD1 or 
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mPLD2 were digested by XbaI and SmaI restriction endonucleases (3 U pro mg plasmid) in a 20 ml 
reaction system (Sambook et al, 1989). The PLD gene fragments were directly separated by 
electrophoresis on 0.8 % (m/v) agarose and extracted by water-saturated phenol and 
chloroform/isoamylethanol (24/1, v/v). Afterwards, PLD gene fragments were precipitated by 
addition of 1/10 volume 3 M sodium acetate (pH 5.2) and the same volume of isopropanol at -20°C 
for 30 min. After centrifugation at 13,000 rpm for 30 min at 4°C, the DNA pellet was washed twice 
with 70 % (v/v) ethanol, air dried and finally dissolved in 10 ml H2O. The DNA concentration was 
determined at 260 nm (LKB Biochrom Ultraspec II Spectrophotometer, Pharmacia). In parallel, 10 
mg pAdTrack-CMV vector was digested with XbaI and EcoRV restriction endonucleases, and the 
linearized vector was extracted, precipitated and washed as described above. The 5’-ends of 
linearized vector DNAs were dephosphorylated with alkaline phosphatase (1 U pro pMol 5’-end of 
linearized vector) for 30 min at 37°C. Thereafter, the dephosphorylated vectors were extracted using 
the “QIAquick” column (Qiagen) and eluted in 30 ml H2O. The DNA concentration was determined 
at 260 nm. 300 ng dephosphorylated pAdTrack-CMV vector were mixed with PLD inserts at a 
molar ratio of 1:3 (vector:insert) and adjusted with H2O to 8.5 ml. The mixture was incubated at 
45°C for 5 min, followed by cooling down on ice. 1 ml 10 ´ ligation buffer (Promega) and 5 U T4-
DNA-ligase were added and incubated at 4°C overnight or, alternatively, at 16°C for 4 h 
(Thermoblock, Eppendorf). 50 - 300 ng of the ligation mixture DNA was transformed in DH10B E. 
coli by the electroporation method (see 3.2.2.2).  
To screen for the pAdTrack-PLD clones, 3 ml E. coli culture in LB medium from each 
selected colony were centrifuged for 2 min at 6,000 rpm at RT (Megafuge 1.0R, Heraeus). The 
bacteria were resuspended in 250 ml TELT lysis buffer and incubated on ice for 5 min. Digestion 
was performed with 5 ml 50 mg/ml lysozyme for 5 min. Afterwards, the mixture was heated for 1 min 
at 95°C (Thermoblock, Eppendorf), followed by incubation for 5 min on ice. After centrifugation for 
10 min at 12,000 rpm (Megafuge 1.0R, Heraeus), the plasmid-containing supernatant was mixed 
with 500 ml 100 % ethanol and incubated for 15 min at RT. The precipitated plasmids were rinsed 
with 80 % ethanol, air dried and dissolved in 10 ml H2O. The plasmids were digested by the 
appropriate restriction endonucleases. Once the right clone (pAdTrack-PLD) was confirmed, its 
corresponding culture was amplified in 500 - 1000 ml LB medium with appropriate antibiotics for 
large-scale purification (Qiagen, maxi-prep kits).  
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Fig. 5: Schematic outline of the AdEasy System. The gene of interest is first cloned into a shuttle 
vector, e.g. pAdTrack-CMV. The resultant plasmid is linearized by restriction endonuclease PmeI and 
subsequently cotransformed into E. coli BJ5183 cells with an adenoviral backbone plasmid, e.g. 
pAdEasy-1. Recombinants are selected for kanamycin resistance and confirmed by restriction 
endonuclease analyses. Finally, the PacI-linearized recombinant plasmid is transfected into adenovirus-
packaging cell lines, e.g. HEK-293 cells. Recombinant adenoviruses are typically generated within 7-12 
days. The "left arm" and "right arm" represent the regions mediating homologous recombination 
between the shuttle vector and the adenoviral backbone vector. An, polyadenylation site; Bm, BamHI; 
RI, EcoRI; LITR, left-hand inverted terminal repeat and packaging signal; RITR, right-hand inverted 
terminal repeat; Sp, SpeI (He et al., 1998). 
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TBE buffer, pH 8.0  
 
 
 
TELT lysis buffer, pH 7.4 
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3.2.19.2 Homologous recombination 
 
1 mg pAdTrack-PLD was linearized with PmeI. After extraction by phenol-chloroform-
isoamylethanol and precipitation by ethanol (see 3.2.19.1), the linearized pAdTrack-PLD in 10 ml 
H2O was co-transformed with 500 ng supercoiled adenoviral backbone pAdEasy-1 vector in 40 ml 
electrocompetent BJ5183 E. coli by the electroporation method (see 3.2.2.2; West, 1994). After 
incubation for 45 min in 1 ml SOC medium at 37°C, the BJ5183 E. coli was plated on LB 
kanamycin agar plates and incubated at 37°C overnight. Small clones were picked up for plasmid 
mini-preparation as described in 3.2.19.1. To determine the right recombinants (pAdEasy-PLD), the 
plasmids were screened by NdeI digestion. Finally, 1 ml of the correct recombinant plasmid was 
transformed into DH10B E. coli for large-scale purification (Qiagen, maxi-prep kits). 
 
3.2.19.3 Preparation of high titer virus stock 
 
30 mg pAdEasy-PLD were digested with PacI to expose its inverted terminal repeats for 
virus particle formation (Chartier et al., 1996). The linearized pAdEasy-PLD was extracted by 
phenol-chloroform-isoamylethanol, precipitated by ethanol and dissolved in 10 ml H2O (see 
3.2.19.1). HEK-293 wild-type cells on 145-mm culture dishes (~70 % confluence) were 
transfected with the linearized pAdEasy-PLD by the lipofectamine method (see 3.2.4.2). GFP 
expression was daily monitored by fluorescence microscopy (Zeiss Axiovert S100, ACHROPLAN 
10 ´ / 0.25 Ph1). After 7 - 10 days, the cells were harvested by centrifugation at 1,700 rpm for 5 
3. Materials and Methods 
 
 50
min at 4°C and resuspended in 10 ml DMEM/F12 medium. To release the viral particles, the cells 
were three times repetitively snap-frozen in liquid nitrogen and thawed at 37°C. The lysates were 
centrifuged at 2,200 rpm for 10 min at 4°C (Megafuge 1.0R, Heraeus), and the viruses (in the 
supernatant) were directly amplified or stored at -20°C. For virus amplication, HEK-293 cells on 
145-mm culture dishes were washed with FCS-free DMEM/F12 medium, incubated with 0.4 ml 
virus-containing supernatant and 4 ml DMEM/F12 medium (2 % FCS) at 37°C for 30 min. 
Thereafter, 16 ml DMEM/F12 (10 % FCS) were added. Cell lysis and green fluorescence became 
evident at 2 - 3 days post infection. The cells were harvested in 10 ml DMEM/F12 medium and 
lysed by three freeze/thaw cycles. Typically, the amplification procedure resulted in at least a 10-fold 
increase in viral particles in the supernatant.  
To produce high-titer virus stock, HEK-293 cells (30 x 145-mm culture dishes) were 
infected with virus supernatant (~5 MOI). The infected cells were harvested as described above, 
and the lysates incubated for 30 min with 175 ml 2 M MgCl2, 100 ml 10 mg/ml RNase A and 60.2 
ml 1 mg/ml DNase I at 37°C. After centrifugation at 3,000 rpm for 30 min at 4°C (Megafuge 1.0R, 
Heraeus), the virus-containing supernatant was extracted two times with an  equal volume of 
trichlorotrifluoroethane (with centrifugation at 3,400 rpm for 5 min at 4°C) and transferred into a 
sterile Falcon tube. The remaining pellet was washed with DMEM/F12 medium, resuspended in 
Murakami buffer and stored at -80°C. A CsCl gradient was carefully built up in a centrifuge tube 
(Beckman No. 326814) with equal volumes of 1.46 g/ml and 1.2 g/ml CsCl, respectively, and the 
virus-containing supernatant was loaded on top of the gradient. The gradient was centrifuged at 
35,000 rpm for 16 h at 10°C (L7-55 Ultracentrifuge, Beckman). The interphase was transferred 
with a syringe into a Slide-a-Lyzer for dialysis (2 ´ 2 h against 2 L Ca2+/Mg2+-free PBS, 1 ´ 
overnight against 2 L virus storage buffer). The virus solution was mixed with an equal volume of 
filter-sterilized virus storage buffer containing 50 % glycerol and stored at -20°C. 
 
3.2.19.4 Virus titration and infection of cells 
 
100 ml virus suspension or stock were mixed with 5 ml 10 mg/ml proteinase K (cleaving the 
polypeptide of virus particles) and 2.7 ml 20 % (m/v) SDS (dissolving the virus capsule) and 
incubated for 2 h at 55°C. Thereafter, the proteins were three times extracted with 300 ml chloropan 
and the virus DNA-containing aqueous phase was concentrated in a microconcentrator (Centricon 
10) by centrifugation at 6,000 rpm for 30 min at 4°C (Sorvall RC-5B, DuPont). The concentrated 
DNA was separated by electrophoresis on 0.8 % (m/v) agarose, together with different amounts (10 
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- 30 ng) of purified pAdEasy-PLD plasmids. The titer of the virus stock was roughly estimated by 
comparing the thickness of the DNA bands of the virus DNA with the pAdEasy-PLD plasmids (21 
ng DNA @ 6.2 ´ 108 adenovirus particles; 30 virus particles @ 1 biological active virus). 
Cells on 145-mm culture dishes (~70 % confluence) were washed with FCS-free 
DMEM/F12 medium and infected with the appropriate amount of virus stock (~5 MOI). Viral 
infection was monitored by visualization of GFP reporter, that is incorporated into the viral 
backbone, by fluorescence microscopy (see 3.2.19.3).  
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3.2.20 Data analysis 
 
Graphs were generated with GraphPad Prism (version 3.02, 2000). All experiments (if not 
indicated otherwise) were performed in triplicate. Data shown in figures are mean ± S.D. of 
representative experiments or mean ± S.E. of n independent experiments. Comparisons between 
means were performed with either the Student’s paired t test or one-way analysis of variance test. 
Confocal laser microscopy images were processed by the Image Pro Plus software (version 4.5; 
Media cybernatics, Inc., Crofton, MD, USA). 
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4. Results 
 
4.1 Specific requirement of G12-type G proteins for M3 mAChR 
signaling to PLD 
 
As nearly every G protein-coupled receptor that stimulates PIP2-specific PLC also 
causes PLD stimulation, it has been supposed that stimulation of PLD ensues from PLC 
activation with subsequent increase in cytoplasmic Ca2+ concentration and activation of PKC 
isoforms (Exton, 199; Cockcroft, 2001; Liscovitch et al., 2001; Exton, 2002). In HEK-293 
cells, the G protein-coupled M3 mAChR couples to both PLC and PLD via a PTX-insensitive 
mechanism (Peralta et al., 1988; Offermanns et al., 1994; Schmidt et al., 1994), but 
stimulation of PLD by the M3 mAChR agonist, carbachol, was not affected by PKC inhibition 
(Schmidt et al., 1994; Rümenapp et al., 1997). Additional work demonstrated that regulation 
of PLD by PMA-responsive PKC lies downstream of tyrosine kinase receptors (Schmidt et al., 
1998; Voß et al., 1999). Thus, as the M3 mAChR couples to PLC most likely via Gq-type G 
proteins (Offermanns et al., 1994), it was considered that the receptor couples to PLD via Gq 
proteins as well, or that two distinct PTX-insensitive G proteins mediate receptor coupling to 
the two phospholipases. 
To determine the type of PTX-insensitive G protein mediating M3 mAChR-PLD 
coupling in comparison to M3 mAChR-PLC coupling, we transiently transfected HEK-293 
cells with expression vectors encoding for mutants (wild-type and constitutively active) of the 
a-subunits of G12,  G13 and Gq. Expression of the individual Ga subunits was examined by 
immunoblotting with specific antibodies (Figs. 6A and 7A; Insets). In cells overexpressing 
wild-type Gaq, both basal and carbachol-stimulated PLC activities were enhanced by 3- to 5-
fold (Fig. 6B). Expression of constitutively active R183C Gaq caused an even larger increase 
in basal PLC activity, which was not further enhanced by carbachol (Fig. 7B). Despite this 
marked PLC stimulation, neither basal nor carbachol-stimulated PLD activities were altered 
by the expression of R183C Gaq (Fig. 7A). 
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Fig. 6: Effects of overexpression of wild-type Ga  proteins on PLD and PLC responses to M3 
mAChR activation. M3 mAChR-expressing HEK-293 cells were transfected with empty expression 
vectors (Con, C) and expression plasmids for Ga12, Ga13 or Gaq (100 µg each). After 48 h, PLD (A) 
and PLC (B) activities were determined by measuring accumulation of [3H]PtdEtOH and [3H]IPx, 
respectively, in the absence (Basal) and presence of 1 mM carbachol (Carb)  (n = 4). Inset: 
Immunoblots of Gaq, Ga12 and Ga13 with specific antibodies. 
 
 
 
 
On the other hand, in cells overexpressing either (wild-type and constitutively active) 
Ga12 or Ga13, the PLD response to carbachol (1 mM) was increased by 2-fold compared to 
control cells, leaving basal PLD activity unaffected (Figs. 6A and 7A). Coexpression of 
constitutively active Ga12 and Ga13 led to a strong, receptor- independent increase in basal 
PLD activity (Fig. 8). In contrast, overexpression of eithe r (wild-type and constitutively active) 
Ga12 or Ga13 did not modify M3 mAChR signaling to PLC (Figs. 6B and 7B). Furthermore, 
PLD stimulation by the phorbol ester PMA (100 nM) was not affected by the overexpression 
of constitutively active Ga12, Ga13 or Gaq (Fig. 9), which is line with the finding that 
regulation of PLD by PMA-responsive PKC is triggered by tyrosine kinase receptors, but not 
by the M3 mAChR, in HEK-293 cells (Schmidt et al., 1994; Voß et al., 1999). These data 
suggested that the M3 mAChR couples specifically to PLD via G12-type G proteins. 
 
0.1
0.2
0.3
0.4
0.5
0
Basal
Carb
 Con    Ga12   Ga13    Gaq
p<0.01
p<0.001
  C    Gaq      C      Ga12   C     Ga13
A
P
td
E
tO
H
 (
%
 o
f 
ph
os
ph
ol
ip
id
s)
0
10
20
30
40
50
60
70
80
Basal
Carbachol
[3
H
]IP
x
 fo
rm
at
io
n 
(c
pm
 x
 1
0
-3
 x
 m
g
-1
)
p<
0.
00
1
p<0.0001B
 Con    Ga12   Ga13    Gaq
4. Results 
 
 54
 
Fig. 7: Effects of expression of constitutively active Ga proteins on PLD and PLC responses to 
M3 mAChR activation. M3 mAChR-expressing HEK-293 cells were transfected with empty 
expression vectors (Con, C) and expression plasmids for Q229L Ga12, Q226L Ga13 or R183C Gaq (50 
µg each). After 48 h, PLD (A) and PLC (B) activities were determined by measuring accumulation of 
[3H]PtdEtOH and [3H]IPx, respectively, in the absence (Basal) and presence of 1 mM carbachol (Carb) 
(n = 4). Inset: Immunoblots of Q229L Ga12, Q226L Ga13 and R183C Gaq with specific antibodies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 8: Receptor-independent PLD stimulation by coexpression of constitutively active Ga12 plus 
Ga13. M3 mAChR-expressing HEK-293 cells were transfected with empty expression vectors (Control) 
and expression plasmids for Q229L Ga12, Q226L Ga13 or Q229L Ga12 plus Q226L Ga13 (Both) (10 
µg each). After 48 h, [3H]PtdEtOH accumulation was determined in the absence (Basal) and presence 
of 1 mM carbachol (n = 3).  
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Fig. 9: Lack of effect of Ga  proteins on PLD stimulation by PMA. M3 mAChR-expressing HEK-
293 cells were transfected with empty expression vectors (Control) and expression plasmids for 
Q229L Ga12, Q226L Ga13 or R183C Gaq (50 µg each). After 48 h, [3H]PtdEtOH accumulation was 
determined in the absence (Basal) and presence of 100 nM PMA (n = 3).  
 
 
To determine the endogenous G protein subtype mediating the coupling of the M3 
mAChR to PLD and PLC, we made use of the two RGS proteins, RGS4 and the RGS 
homology domain of Lsc (Lsc-RGS; a murine homolog of a Rho-specific GEF), which act as 
GAPs for Gaq and Ga12 family members, respectively (Druey et al., 1996; Dohlman & 
Thorner, 1997; Wieland & Chen, 1999; de Vries et al., 2000; Ross & Wilkie, 2000). 
Expression of the RGS proteins was proven by immunoblotting with specific antibodies (Fig. 
10A; Inset). The transient expression of Lsc-RGS reduced by about 50 % the PLD response to 
carbachol, whereas expression of RGS4 was without effect (Fig. 10A). In contrast, expression 
of RGS4 attenuated the PLC response to carbachol by about 50 %, whereas the expression of 
Lsc-RGS did not alter PLC signaling (Fig. 10B). As shown in Fig. 11, the reduction of PLD 
stimulation induced by Lsc-RGS was mimicked by transient expression of G228A Ga12 or 
G225A Ga13, which act as dominant-negative mutants of Ga12 and Ga13, respectively (Gohla 
et al., 1999).  
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Fig. 10: Effects of transient expression of RGS4 and Lsc-RGS on PLD and PLC stimulation by 
the M3 mAChR .  M3 mAChR-expressing HEK-293 cells were transfected with empty expression 
vectors (Control, Con) and expression plasmids for flag-tagged RGS4 or myc-tagged Lsc-RGS (100 
µg each). After 48 h, PLD (A) and PLC (B) activities were determined in the absence (Basal) and 
presence of 1 mM carbachol. Data are representative of four experiments. Inset: Immunoblot of flag-
tagged RGS4 and myc-tagged Lsc-RGS with specific antibodies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 11: Inhibition of the PLD response to the M3 mAChR by dominant-negative Ga12 and Ga 13. 
M3 mAChR-expressing HEK-293 cells were transfected with empty expression vectors (Control) and 
expression plasmids for G228A Ga12 or G225A Ga13 (100 µg each). After 48 h, PLD activity was 
determined in the absence (Basal) and presence of 1 mM carbachol (n = 3). Inset: Immunoblots of 
G228A Ga12 and G225A Ga13 with specific antibodies. 
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In addition, the cells were infected with adenoviruses encoding RGS4 and Lsc-RGS, 
as this approach results in high efficient gene transfer (He et al., 1998; Young & Mautner, 
2001; Armstrong et al., 2002). Expression of the individual adenoviruses was examined by 
expression of  GFP (data not shown; see also Fig. 17) or immunoblotting with specific 
antibodies (Fig. 12A; Inset). The expression of RGS4 by adenoviral infection was without any 
effect on PLD stimulation by the M3 mAChR (Fig. 12A). Neither the maximal extent nor the 
concentration dependence of PLD stimulation by carbachol was altered in RGS4-expressing 
cells, compared with control cells infected with an adenovirus encoding LacZ. In contrast, the 
carbachol- induced PLD stimulation was blunted (by about 80 %) by the expression of Lsc-
RGS (Fig. 12A). On the other hand, adenoviral expression of Lsc-RGS did not affect the 
stimulation of PLC activity at any carbachol concentration, whereas PLC stimulation was 
strongly reduced (by about 70 %) by the expression of RGS4 (Fig. 12B). Taken together, 
expression (transient or by infection with recombinant adenoviruses) of RGS4 or Lsc-RGS in 
HEK-293 cells strongly indicates that Gq- and G12-type G proteins specifically mediate the 
coupling of the M3 mAChR to PLC and to PLD, respectively. Likewise, expression of 
dominant-negative mutants of Ga12 and Ga13 demonstrated that both heterotrimeric G 
proteins are indispensable to achieve full activation of PLD by the M3 mAChR.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 12: Effects of adenoviral expression of RGS4 and Lsc-RGS on PLD and PLC stimulation by 
the M3 mAChR . M3 mAChR-expressing HEK-293 cells were infected with recombinant adenoviruses 
encoding LacZ, His6-tagged Lsc-RGS and RGS4 at a MOI = 30. At 48 h later, PLD (A) and PLC (B) 
activities were determined at the indicated concentrations of carbachol. Data are representative of two 
experiments. Inset: Immunoblot of RGS4 and His6-tagged Lsc-RGS with specific antibodies. 
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4.2 Involvement of distinct PLD isoforms in receptor signaling 
to PLD 
 
Regulation of PLD by membrane receptors in HEK-293 cells involves apparently 
distinct signaling cascades (Schmidt et al., 1994; Rümenapp et al., 1995; Schmidt et al., 
1996b; Schmidt et al., 1999; Voß et al., 1999). In particular, as shown above, stimulation of 
PLD by the M3 mAChR is mediated by the G12-type G proteins, Ga12 and Ga13. Additional 
work demonstrated that the PLD response to the G protein-coupled M3 mAChR depends on 
ARF and Rho GTPases, but not PKC. In contrast, stimulation of PLD by tyrosine kinase 
receptors is triggered by PKC-a and a Ras/Ral-GEF/Ral-dependent signaling cascade (see 
Introduction). As HEK-293 cells endogenously express both, PLD1 and PLD2 (Schmidt et al., 
1998; Schmidt et al., 1999), it was considered that the distinct membrane receptors may 
signal to both PLD isoforms, or that PLD1 and PLD2 are differentially activated by these 
receptors. 
As a first approach to gain insights into the regulation of PLD1 and PLD2 by 
membrane receptors in HEK-293 cells, we transiently transfected the cells with expression 
vectors encoding for catalytically inactive PLD mutants. Expression of the PLD mutants was 
probed by immunoblotting with specific antibodies (Fig. 13A; Inset). As shown in Fig. 13, 
expression of either mutant had only small effects on basal PLD activity. However, 
expression of the catalytically inactive K898R PLD1 mutant reduced by about 50 % the M3 
mAChR action (Fig. 13A). In contrast, expression of  the catalytically inactive K758R PLD2 
mutant only sightly affected PLD stimulation by carbachol. However, this mutant was not 
inactive. Expression of catalytically inactive PLD2 suppressed by about 60 % stimulation of 
PLD by PMA-responsive PKC (Fig. 13B). In contrast, expression of K898R PLD1 failed to 
inhibit PLD stimulation by PMA. As regulation of PLD by PMA-responsive PKC is triggered 
by tyrosine kinase receptors (Voß et al., 1999), the effects of the catalytically inactive PLD 
mutants on EGF receptor signaling was analyzed as well. As shown in Fig. 13C, expression of 
catalytically inactive PLD2 reduced specifically PLD stimulation by EGF. Thus, in HEK-293 
cells the M3 mAChR signals most likely primarily to PLD1, whereas tyrosine kinase receptors 
signal primarily to PLD2. 
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Fig. 13: Effects of catalytically inactive PLD isoform mutants on PLD stimulation by carbachol, 
PMA and EGF. M3 mAChR-expressing HEK-293 cells were transfected with empty expression 
vectors (Control, Con) and expression plasmids for K898R PLD1 or K758R PLD2 (150 µg each). 
After 48 h, [3H]PtdEtOH formation was determined in the absence (Basal) and presence of 1 mM 
carbachol (A), 100 nM PMA (B) or 100 ng/ml EGF (C) (n = 3-5). Inset: Immunoblot of PLD1 and 
PLD2 with specific antibodies.  
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4.3 Generation of recombinant PLD adenoviruses 
 
Based on the promising findings with recombinant adenoviruses encoding RGS4 
and Lsc-RGS (see also 4.1), adenoviruses encoding wild-type as well as catalytically inactive 
PLD1 and PLD2 mutants were generated for future work on the cellular role of these PLD 
enzymes in receptor action. To insert the PLD mutants into the shuttle vector pAdTrack-CMV 
(see also Fig. 5), wild-type and catalytically inactive PLD1 and PLD2 were excised from the 
pCGN vector using the XbaI + SmaI endonucleases. The size of PLD1 is about 3.5 kb and can 
be cut out by the restriction endonuclease BglII at position 685 and by the restriction 
endonuclease Nde I at position 1026. The size of PLD2 is about 3.0 kb and can be cut by Bgl 
II at position 2576, however PLD2 exhibits no NdeI cutting site. In addition, PLD1 and PLD2 
did not contain cutting sites for the restriction endonucleases PmeI and PacI (Fig. 14).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 14: Scheme of PLD1 and PLD2 subcloning into pAdTrack-CMV and pAdEasy-1. CRI-CRIV, 
conserved regions I to IV; PH, pleckstrin homology; PX, phox homology; ori, origin; Kan, kanamycin; 
LITR, left-hand inverted terminal repeats; GFP, green fluorescent protein; CMV, cytomegalovirus; 
AMP, ampicillin. For further explanation, see text and also Fig. 5. 
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The pAdTrack-CMV shuttle vector (9.2 kb; see also Fig. 5) was linearized with Xba 
I + EcoR V in its multicloning site and dephosphorylated to minimize the false-positive 
ligations. In these experiments, ligation was quite difficult due to the generation of blunt ends 
from EcoR V cutting of pAdTRack-CMV and Sma I cutting of PLD inserts. The plasmid 
DNA from candidate clones were screened with Bgl II digestion. As shown in Fig. 15, the 
right pAdTrack-PLD1 constructs were excised with a characteristic band of around 700 bp 
between the position 685 in PLD1 and the position 2398 in pAdTrack-CMV by BglII. For 
pAdTrack-PLD2, the characteristic band was around 2600 bp from the position 2576 in PLD2 
to position 2398 in pAdTrack-CMV (Figs. 14 and 15).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 15: Subcloning of PLD inserts into pAdTrack-CMV. PLD inserts derived from the pCGN 
vectors were ligated into pAdTrack-CMV. pAdTrack-PLD constructs were purified, digested with the 
restriction endonuclease BglII and screened by electrophoresis on 0.8 % (m/v) agarose. (M), 1Kb 
DNA ladder marker; Lanes 1-4, wild-type PLD1 in pAdTrack-CMV; Lanes 5-8, wild-type PLD2 in 
pAdTrack-CMV; Lanes 9-11, catalytically inactive PLD2 in pAdTrack-CMV. Positive pAdTrack-
PLD clones were marked with "*".  
 
To achieve homologous recombination and generation of the recombinant 
adenoviruses, we used the restriction endonuclease NdeI to select pAdEasy-PLD 
recombinants. The restriction endonuclease NdeI has 3 cutting sites on the backbone 
adenoviral vector pAdEasy-1, 4 cutting sites on pAdTrack-PLD1 and 3 cutting sites on 
pAdTrack-PLD2 (Fig. 14). In case of correct homologous recombination between PmeI-
linearized pAdTrack-PLD1 and supercoiled pAdEasy-1 (Fig. 14), the 4 cutting sites of NdeI 
on pAdTrack-PLD1 took place at the cutting site 1673 of Nde I on pAdEasy-1. Correct 
pAdEasy-PLD1 constructs were excised by NdeI into 6 bands. PLD1 inserts were distributed 
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into two bands. The characteristic smallest band was about 1.3 kb between position 1026 in 
PLD1 and position 2670 in pAdTrack-CMV. The second band was about 3.1 kb between 
position 1705 in pAdTrack-CMV and position 1026 in PLD1 (Fig. 16). As PLD2 has no NdeI 
cutting site, digestion by NdeI of correct pAdEasy-PLD2 constructs produced 5 bands. The 
PLD2-containing bands were of about 4.3 kb between position 1705 and position 2670 in 
pAdTrack-CMV. The other four bands were identical to the pattern obtained by NdeI cut of 
pAdEasy-PLD1. The biggest band was by about 14 kb between position 2670 in pAdTrack-
CMV and position 19,683 in pAdEasy-1 (Figs. 14 and 16). Thus, employing such cloning 
strategy, recombinant adenoviruses encoding for various PLD  mutants were obtained. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 16: Generation of homologous recombinants in BJ5183 E. coli cultures. pAdTrack-PLD 
constructs were linearized by PmeI, purified and cotransformed with the pAdEasy-1 vector into 
BJ5138 E. coli cultures for homologous recombination. Possible pAdEasy-PLD recombinants were 
purified, digested with the restriction endonuclease NdeI and screened by electrophoresis on 0.8 % 
(m/v) agarose. Various catalytically inactive pAdEasy-PLD1 recombinants (A), wild-type PLD2 
recombinant (lane 1) and catalytically inactive PLD2 recombinant (lane 2) (B). (M), Lamda DNA / 
EcoRI and HindIII marker. Positive pAdEasy-PLD constructs were marked with "*". 
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The recombinant adenoviral plasmids encoding wild-type PLD1 and catalytically 
inactive PLD2 were re-transformed into DH10B E. coli. As illustrated in Fig. 17, the high 
titer viral stock infected the HEK-293 cells (Fig. 17 A-D) and PC12 cells (Fig. 17 E-H) 
efficiently and the comet- like signals of recombinant PLD adenovirus foci became apparent at 
3 - 4 days post infection. In addition, as verified by immunoblotting with specific antibodies, 
adenoviral infection of HEK-293 cells with wild-type PLD1 and catalytically inactive PLD2 
resulted in strong overexpression of the PLD isoforms in the cells (Fig. 17I). Similar results 
were obtained by infection of HEK-293 and PC12 cells with the recombinant adenoviruses 
encoding for wild-type PLD2 and catalytically inactive PLD1 (data not shown). Thus, 
recombinant adenoviruses encoding wild-type and catalytically inactive PLD mutants were 
generated which are obviously capable to successfully infect various cell types resulting in 
expression of PLD1 and PLD2, as shown by GFP expression using the fluorescence 
microscope and by immunoblotting with specific antibodies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 17: Adenoviral expression of wild-type PLD1 and catalytically inactive PLD2 in HEK-293 
and PC12 cells. Linearized pAdEasy-GFP-PLDs were infected into HEK-293 wild-type cells. Viruses 
were subsequently produced and purified until high titer viral stock was successfully harvested. 
Thereafter, 1 ml of virus storage buffer (Control; A, C, E, G) or recombinant adenovirus encoding 
wild-type PLD1 (Wild-type PLD1; B, D, F, H) was used to infect HEK-293 cells (upper panel) and 
PC12 cells (lower panel) cultured on 145-mm dishes. Viral infection was monitored by GFP 
expression using the fluorescence microscope. (A, B, E, F): DIC, Differential interference contrast; 
(C, D, G, H): GFP signal. Shown are representative images. I: Immunoblots of PLD1 and PLD2 with 
specific antibodies of lysates of control (Con) HEK-293 cells and HEK-293 cells infected with 
adenoviruses encoding wild-type PLD1 and catalytically inactive PLD2.  
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4.4 LIM-kinase mediates PLD stimulation by G protein-
coupled receptors 
 
In HEK-293 cells, PLD stimulation by RhoA is apparently not caused by direct 
RhoA-PLD interaction, but rather involves indirect Rho-dependent mechanisms. For example, 
stimulation of PIP 5-kinase by RhoA elevates the cellular level of PIP2, which profoundly 
affects PLD enzyme activity in HEK-293 cells (Schmidt et al., 1996; Schmidt et al., 1996c; 
Schmidt et al., 1999; Oude Weernink et al., 2000a). Additional work demonstrated that Rho-
kinase, a member of the Rho effector family, mediates stimulation of PLD by the M3 mAChR 
(Schmidt et al., 1999) and stimulates PIP 5-kinase activity as well (Oude Weernink et al., 
2000b). As PLD enzymes do not directly interact with, or are phosphorylated by Rho-kinase 
(Schmidt et al., 1999), regulation of PLD by Rho/Rho-kinase obviously involves additional, 
yet undefined, signaling components. As Rho-kinase modulates, at least in part, the 
reorganization of the actin cytoskeleton by activating LIM-kinase (Aspenström, 1999; 
Kaibuchi et al., 1999; Amano et al., 2000; Bishop & Hall, 2000), it was considered that 
stimulation of PLD by Rho/Rho-kinase may involve LIM-kinase as well. 
To test this hypothesis, HEK-293 cells were transiently transfected with expression 
vectors encoding for mutants (wild-type, constitutively active and kinase-deficient) of LIM-
kinase. Substitution of threonine by two glutamic acid residues at position 508 (T508EE) 
generates a constitutively active LIM-kinase mutant (CAT LIM-kinase), which is 
unresponsive to Rho/Rho-kinase-dependent phosphorylation at position 508, whereas a 
mutation at position 460 (Asp®Ala) (D460A) abolishes LIM-kinase activity (kinase-deficient 
LIM-kinase, KD LIM-kinase; Pröschel et al, 1995; Edwards & Gill, 1999). Expression of the 
HA-tagged LIM-kinase mutants was examined by immunoblotting with a specific antibody 
(Fig. 18A; Inset). As illustrated in Fig. 18A, overexpression of wild-type LIM-kinase 
markedly increased PLD stimulation by the M3 mAChR, by about 2.5-fold. Expression of 
constitutively active LIM-kinase (T508EE LIM-kinase) potentiated PLD stimulation by 
carbachol even more pronounced, by about 4-fold (Fig. 18B), whereas overexpression of 
kinase-deficient LIM-kinase (D460A LIM-kinase) reduced PLD stimulation by the M3 
mAChR by about 60 % (Fig. 18C). None of these LIM-kinase mutants altered basal PLD 
activity and stimulation of PLD by PMA-responsive PKC (Figs. 18 and 19). Thus, LIM-
kinase triggers specifically regulation of PLD by the G protein-coupled M3 mAChR. 
 
 
 
4. Results 
 
 66
 
Fig. 18: Effect of LIM -kinase on PLD stimulation by the M3 mAChR. M3 mAChR-expressing 
HEK-293 cells were transfected with empty expression vector (200 µg pUCD2, 0, Con) and the 
indicated concentrations of HA-tagged wild-type LIM-kinase (A), HA-tagged constitutively active 
LIM-kinase (T508EE LIM-kinase) (B) or HA-tagged kinase-deficient LIM-kinase (D460A LIM-
kinase) (C). After 48 h, [3H]PtdEtOH accumulation was determined in the absence (Basal) and 
presence of 1 mM carbachol (n = 2-4). Inset: Immunoblot of HA-tagged wild-type LIM-kinase, HA-
tagged T508EE LIM-kinase and HA-tagged D460A LIM-kinase with a specific antibody.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 19: Lack of effect of LIM-kinase on PLD stimulation by PMA. M3 mAChR-expressing HEK-
293 cells were transfected with empty expression vector (Control, 200 µg pUCD2) and expression 
plasmids for HA-tagged wild-type LIM-kinase, HA-tagged T508EE LIM-kinase (100 µg each) or HA-
tagged D460A LIM-kinase (200 µg). After 48 h, PLD activity was determined in the absence (Basal) 
and presence of 100 nM PMA (n = 3). 
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To gain insights into the mechanisms of PLD regulation by LIM-kinase, we studied 
the effect of purified recombinant LIM-kinase on PLD activity in HEK-293 cell membranes. 
Addition of recombinant LIM-kinase (2 µM) in the presence of 1 mM MgATP largely 
increased PLD activity, similar as, but not additive with, GTPgS-activated RhoA or Rho-
kinase (Fig. 20). These data suggest that regulation of PLD by LIM-kinase is enabled by 
Rho/Rho-kinase signaling. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 20: Stimulation of PLD activity in HEK-293 cell membranes by recombinant Rho-kinase 
and LIM-kinase. PLD activity was measured in HEK-293 cell membranes for 15 min at 30°C in the 
presence of 1 mM MgATP without (Control) and with recombinant constitutively active Rho-kinase 
or LIM-kinase (2 µM each) alone (Basal) or in the presence of recombinant GTPgS-activated RhoA 
(10 µg RhoA + 100 µM GTPgS; GTPgS/RhoA). Data are representative of two experiments. Inset: 
Coomassie blue staining of GST-tagged Rho-kinase and immunoblot of flag-tagged LIM-kinase with a 
specific antibody.  
 
 
To define whether PLD potentiation by LIM-kinase is indeed Rho- and Rho-kinase- 
dependent, cotransfection experiments were performed with the Rho-inactivating C3 
transferase (Aktories & Just, 1993) and a dominant-negative Rho-kinase mutant, which lacks 
the Rho-binding and PH domains of Rho-kinase (RB/PH(TT); Oshiro et al., 1998). 
Expression of C3 transferase and RB/PH(TT) reduced PLD stimulation by the M3 mAChR 
and fully prevented the potentiating effect of wild-type LIM-kinase (Figs. 21A and 21B). In 
contrast, cotransfection of C3 transferase or RB/PH(TT) did not inhibit PLD potentiation by 
the Rho/Rho-kinase-independent constitutively active LIM-kinase (Figs. 21C and 21D).  
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Fig. 21: PLD potentiation by LIM-kinase is Rho- and Rho-kinase-dependent. M3 mAChR-
expressing HEK-293 cells were transfected with empty expression vectors (Con), 100 µg wild-type 
LIM-kinase (A, B), 100 µg C3 transferase (A, C), 100 µg dominant-negative Rho-kinase (RB/PH(TT) 
(B, D), 100 µg constitutively active LIM-kinase (CAT) (C, D), wild-type LIM-kinase plus either C3 
transferase (Both) (A) or RB/PH(TT) (Both) (B), and constitutively active LIM-kinase plus either C3 
transferase (Both) (C) or RB/PH(TT) (Both) (D). After 48 h, PLD activity was determined in the 
absence (Basal) and presence of 1 mM carbachol (Carb) (n = 2-5).  
 
As LIM-kinase can also be activated by Rac and Cdc42 signals (Yang et al., 1998; 
Edwards et al., 1999), we transiently transfected the cells with dominant-negative mutants of 
Rac1 (T17N Rac1) and Cdc42 (T17N Cdc42). However, expression of these two Rho-like 
GTPases did neither affect PLD stimulation by the M3 mAChR nor PLD potentiation caused 
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by overexpression of LIM-kinase (Fig. 22). Thus, PLD potentiation by LIM-kinase depends 
on Rho/Rho-kinase, but not Rac1 and Cdc42, signals. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 22: PLD potentiation by LIM-kinase does not depend on Rac1 and Cdc42. M3 mAChR-
expressing HEK-293 cells were transfected with empty expression vectors (Con), 100 µg wild-type 
LIM-kinase (WT) (A, B), 100 µg dominant-negative Rac1 (T17N Rac1) (A), 100 µg dominant-
negative Cdc42 (T17N Cdc42) (B), wild-type LIM-kinase plus either T17N Rac1 (Both) (A) or T17N 
Cdc42 (Both) (B). After 48 h, [3H]PtdEtOH accumulation was determined in the absence (Basal) and 
presence of 1 mM carbachol (Carb). Overexpression of T17N Rac1 and T17N Cdc42 was examined 
by immunoblotting with specific antibodies (data not shown). Data are representative of three similar 
experiments. 
 
 
To study whether regulation of PLD by Rho-kinase is indeed mediated by LIM-
kinase, we transiently transfected the cells with wild-type Rho-kinase or constitutively active 
Rho-kinase (CAT Rho-kinase), which upon deletion of the Rho-binding domain of Rho-
kinase is unresponsive to Rho (Schmidt et al., 1999), together with kinase-deficient LIM-
kinase. Coexpression of kinase-deficient LIM-kinase with either wild-type Rho-kinase or 
CAT Rho-kinase completely abolished PLD potentiation by both, wild-type Rho-kinase and 
CAT-Rho-kinase mutant (Fig. 23), strongly suggesting that LIM-kinase is in fact a 
downstream effector of Rho-kinase in M3 mAChR signaling to PLD. 
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Fig. 23: PLD potentiation by Rho-kinase is LIM-kinase dependent. M3 mAChR-expressing HEK-
293 cells were transfected with empty expression vectors (Con), wild-type Rho-kinase (WT) (A), 
constitutive ly active Rho-kinase (CAT) (B), 150 µg kinase-deficient LIM-kinase (KD), wild-type Rho-
kinase plus kinase-deficient LIM-kinase (Both) (A) or constitutively active LIM-kinase plus kinase-
deficient LIM-kinase (Both) (B). After 48 h, PLD activity was determined in the absence (Basal) and 
presence of 1 mM carbachol (Carb) (n = 3-4).  
 
 
Stimulation of PLD by the M3 mAChR in HEK-293 cells is obviously the result of 
ARF and Rho signals (Rümenapp et al., 1995; Schmidt et al., 1996b; Schmidt et al., 1999; 
Schürmann et al., 1999; Voß et al., 1999). In line with such a dual regulation, expression of 
constitutively active LIM-kinase largely enhanced PLD stimulation by the M3 mAChR but 
did not cause an increase in basal PLD activity (see Figs. 18 and 21), possibly because active 
ARF is missing. To examine whether PLD potentiation by LIM-kinase requires activated 
ARF and vice versa, we transiently transfected the cells with various mutants of LIM-kinase 
and ARF1. Expression of dominant-negative ARF1, T31N ARF1, which exhib its its 
inhibitory effect most likely by the sequestration of endogenous ARF-specific GEFs (Dascher 
& Balch, 1994), reduced by about 70 % PLD stimulation by carbachol and fully abolished 
PLD potentiation by constitutively active LIM-kinase (Fig. 24A). On the other hand, 
expression of constitutively active ARF1 (Q71L ARF1; Teal et al., 1994) enhanced by about 
2.5-fold PLD stimulation by carbachol leaving basal PLD activity unaffected (Fig. 24B). 
However, coexpression of kinase-deficient LIM-kinase fully prevented PLD potentiation by 
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constitutively active ARF1 (Fig. 24B). Thus, regulation of PLD by the M3 mAChR in HEK-
293 cells is a concerted action of Rho/Rho-kinase/LIM-kinase and ARF signaling cascades. 
 
Fig. 24: PLD stimulation by the M 3 mAChR is a concerted action of ARF and Rho signaling. M3 
mAChR-expressing HEK-293 cells were transfected with empty expression vectors (Con), 
constitutively active LIM-kinase (CAT), dominant-negative ARF1 (T31N ARF1), constitutively active 
LIM-Kinase plus T31N ARF1 (Both) (A), constitutively active ARF1 (Q71L ARF1) (100 µg each), 
150 µg kinase-deficient LIM-kinase (KD) and Q71L ARF1 plus kinase-deficient LIM-kinase (Both) 
(B). After 48 h, [3H]PtdEtOH accumulation was determined in the absence (Basal) and presence of 1 
mM carbachol (Carb) (n = 3-4).  
 
 
 
 
The results obtained by expression of catalytically inactive PLD mutants (see 4.2) 
suggested that the M3 mAChR signals in HEK-293 cells primarily to PLD1, but not to PLD2. 
Therefore, it was assumed that LIM-kinase may preferentially signal to PLD1 as well. To 
study this, the cells were cotransfected with wild-type LIM-kinase together with either 
catalytically inactive PLD1 (K898R PLD1) or catalytically inactive PLD2 (K758R PLD2). As 
illustrated in Fig. 25, coexpression of K898R PLD1, but not K758R PLD2, fully prevented 
PLD potentiation by LIM-kinase. Thus, regulation of PLD acctivity by LIM-kinase signals 
primarily to PLD1, but not to PLD2. 
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Fig. 25: LIM-kinase signals to PLD1. M3 mAChR-expressing HEK-293 cells were transfected with 
empty expression vectors (Con), wild-type LIM-kinase (WT), 150 µg catalytically inactive PLD1 
(K898R PLD1) (A), 150 µg catalytically inactive PLD2 (K758R PLD2) (B) and wild-type LIM-kinase 
plus either K898R PLD1 (Both) (A) or K758R PLD2 (Both) (B). After 48 h, PLD activity was 
determined in the absence (Basal) and presence of 1 mM carbachol (Carb). Data are representative of 
three similar experiments.  
 
 
To study whether regulation of receptor signaling to PLD by LIM-kinase is 
restricted to the M3 mAChR, we stimulated PLD activity in kinase-deficient LIM-kinase-
expressing HEK-293 cells by various agonists of receptors endogenously expressed in HEK-
293 cells (Schmidt et al., 2000). As expected, expression of kinase-deficient LIM-kinase 
largely reduced PLD stimulation by the M3 mAChR (Fig. 26). Most important, LPA receptor 
signaling to PLD was similarly reduced by kinase-deficient LIM-kinase, by about 50 %. In 
contrast, tyrosine kinase receptor (EGF and insulin) signaling to PLD was not changed by 
expression of kinase-deficient LIM-kinase (Fig. 26). Taken together, LIM-kinase seems to be 
indispensable for G protein-coupled receptor signaling to PLD, but not for PLD stimulation 
by tyrosine kinase receptors. 
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Fig. 26: G protein-coupled receptor signaling to PLD depends on LIM-kinase. M3 mAChR-
expressing HEK-293 cells were transfected with empty expression vectors (Control) or with 150 µg 
kinase-deficient LIM-kinase. After 48 h, PLD activity was determined in the absence (Basal) and 
presence of 1 mM carbachol (Carb), 10 µM LPA, 100 ng/ml EGF or 10 µg/ml insulin (n = 3).  
 
 
As it has been hypothesized that LIM-kinase signaling is critically involved in brain 
function via regulation of actin dynamics (Meng et al., 2002), and as it has been recently 
demonstrated that Rho-kinase/LIM-kinase signaling regulates neurite remodeling in N1E-115 
neuroblastoma cells (Yamazaki et al., 2002), we transiently transfected the LIM-kinase 
mutants in these neuronal cells and studied their effects on mAChR signaling to PLD. As 
shown in Fig. 27, overexpression of wild-type LIM-kinase increased PLD stimulation by the 
agonist carbachol by about 30 %. Expression of the constitutively active LIM-kinase 
potentiated PLD stimulation by carbachol by even about 250 %. In contrast, expression of 
kinase-deficient LIM-kinase inhibited carbachol- induced PLD stimulation by about 60 %. 
None of the LIM-kinase mutants changed basal PLD activity in N1E-115 neuroblastoma cells 
(Fig. 27). Thus, LIM-kinase signaling is not only essential for the regulation of actin 
dynamics in neuronal cells, but apparently also for PLD signaling. 
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Fig. 27: Regulation of PLD by LIM-kinase in N1E-115 neuroblastoma cells. N1E-115 
neuroblastoma cells were transfected with empty expression vectors (Control), wild-type LIM-kinase, 
constitutively active LIM-kinase (CAT) or kinase-deficient LIM-kinase (KD) (100 µg each). After 48 
h, PLD activity was determined in the absence (Basal) and presence of 100 µM carbachol (n = 3).  
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4.5 LIM-kinase signals via cofilin to PLD 
 
As LIM-kinase was now identified as a novel player in receptor signaling to PLD, it 
was first assumed that LIM-kinase may directly interact with PLD enzymes, resulting in their 
phosphorylation. However, as illustrated in Fig. 28, purified recombinant LIM-kinase (Fig. 
28A) did neither phosphorylate PLD1 or PLD2 nor bind to the PLD enzymes (Fig. 28B, right 
panel; data not shown). The recombinant LIM-kinase was, however, not inactive. Under 
identical experimental conditions, LIM-kinase phosphorylated wild-type cofilin, but not the 
nonphosphorylatable cofilin mutant, S3A cofilin (Fig. 28B, left panel). As cofilin, a member 
of the actin depolymerization family, is the only LIM-kinase substrate identified so far 
(Bamburg, 1999; Maekawa et al., 1999; Higgs & Pollard, 2001), it was then studied whether 
cofilin is involved in PLD regulation by LIM-kinase. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 28: LIM -kinase does not phosphorylate recombinant PLD1 and PLD2. (A) SDS-PAGE (15 
% (m/v) of purified His6-tagged wild-type cofilin (WT) and nonphosphorylatable cofilin (S3A) (10 µg 
each) stained with Coomassie blue (left panel). Sf9 cells were infected with baculoviruses encoding 
GST, GST-tagged PLD1 or GST-tagged PLD2. After purification, the proteins were separated on 
SDS-PAGE (12.5 % (m/v) (10 µg each), transferred onto nitrocellulose membranes and probed with 
specific antibodies. (B) Recombinant LIM-kinase (1.5 µM) was incubated with wild-type cofilin, S3A 
cofilin (10 µg each), GST, GST-tagged PLD1 or GST-tagged PLD2 (50 µg each) in the presence of [g-
32P]ATP for 45 min at 25°C. Phosphorylated proteins were separated by SDS-PAGE and visualized by 
autoradiography. Data are representative of three to four similar experiments. 
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First, HEK-293 cells were transiently transfected with wild-type cofilin and the 
nonphosphorylatable cofilin mutant, S3A cofilin. Expression of the HA-tagged cofilin 
mutants was verified by immunblotting with a specific antibody (Fig. 29A; Inset). Expression 
of wild-type cofilin largely enhanced, by about 2.5-fold, carbachol- induced PLD stimulation 
(Fig. 29A). In contrast, expression of S3A cofilin suppressed the M3 mAChR response by 
about 50 % (Fig. 29B). Wild-type cofilin and S3A cofilin did not alter basal PLD activity and 
regulation of PLD by PMA-responsive PKC (Fig. 30). Thus, cofilin seems to be specifically 
involved in PLD stimulation by the G protein-coupled M3 mAChR. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 29: Effect of cofilin on PLD stimulation by the M3 mAChR. M3 mAChR-expressing HEK-293 
cells were transfected with empty expression vector (200 µg pCDL-SRa, 0, Con) and the indicated 
concentrations of HA-tagged wild-type cofilin (A) or HA-tagged nonphosphorylatable cofilin (S3A 
Cofilin) (B). After 48 h, PLD activity was determined in the absence (Basal) and presence of 1 mM 
carbachol (Carb) (n = 3-4). Inset: Immunoblot of HA-tagged wild-type (WT) and S3A cofilin (S3A) 
with a specific antibody.  
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Fig. 30: Lack of effect of cofilin on PLD stimulation by PMA. M3 mAChR-expressing HEK-293 
cells were transfected with empty expression vectors (Control, 150 µg pCDL-SRa), 100 µg wild-type 
cofilin or 150 µg S3A cofilin. After 48 h, PLD activity was determined in the absence (Basal) and 
presence of 100 nM PMA (n = 4).  
 
 
 
 
In the following, it was studied whether regulation of PLD activity by cofilin 
requires Rho/Rho-kinase/LIM-kinase signals. As shown in Fig. 31, expression of either the 
Rho-inactivating C3 transferase (Fig. 31A), the dominant-negative Rho-kinase (RB/PH(TT) 
(Fig. 31B) or the kinase-deficient LIM-kinase (Fig. 31C) fully abrogated the stimulatory 
effect of wild-type cofilin on PLD stimulation by carbachol. These data, thus, suggested that 
cofilin is part of the M3 mAChR-initiated Rho/Rho-kinase/LIM-kinase signaling cascade to 
PLD. 
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Fig. 31: PLD potentiation by cofilin requires Rho, Rho-kinase and LIM-kinase. M3 mAChR-
expressing HEK-293 cells were transfected with empty expression vectors (Con), wild-type cofilin 
(WT) (A-C), C3 transferase (A), dominant-negative Rho-kinase (RB/PH(TT) (100 µg each) (B), 150 
µg kinase-deficient LIM-kinase (KD LIM kinase) (C), wild-type cofilin (WT) plus either C3 
transferase (Both) (A), RB/PH(TT) (Both) (B) or kinase-deficient LIM-kinase (Both) (C). After 48 h, 
PLD activity was determined in the absence (Basal) and presence of 1 mM carbachol (Carb) (n = 2-4).  
 
 
 
 
If cofilin functions as downstream effector of LIM-kinase in the regulation of PLD 
by the M3 mAChR, expression of S3A cofilin, which by itself reduced receptor signaling to 
PLD (see Fig. 29), should prevent the stimulatory effect of LIM-kinase on PLD activity.  
Indeed, coexpression of S3A cofilin largely abrogated the stimulatory effect of wild-type 
LIM-kinase (Fig. 32A) and, most important, also of constitutively active LIM-kinase on M3 
mAChR-induced PLD stimulation (Fig. 32B). In line with a specific role of cofilin in M3 
mAChR signaling to PLD, coexpression of  K898R PLD1, but not K758R PLD2, fully 
prevented PLD potentiation by cofilin (Fig. 33). Thus, LIM-kinase seems to signal via cofilin 
specifically to PLD1. 
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Fig. 32: Inhibition of LIM-kinase-induced PLD potentiation by S3A cofilin. M3 mAChR-
expressing HEK-293 cells were transfected with empty expression vectors (Con), wild-type LIM-
kinase (WT) (A), constitutively active LIM-kinase (CAT) (100 µg each) (B), 150 µg S3A cofilin, wild-
type LIM-kinase plus S3A cofilin (Both) (A) or constitutively active LIM-kinase plus S3A cofilin 
(Both) (B). After 48 h, PLD activity was determined in the absence (Basal) and presence of 1 mM 
carbachol (n = 4-6).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 33: Cofilin signaling to PLD1. M3 mAChR-expressing HEK-293 cells were transfected with 
empty expression vectors (Con), 100 µg wild-type cofilin (WT), 150 µg catalytically inactive PLD1 
(K898R PLD1) (A), 150 µg catalytically inactive PLD2 (K758R PLD2) (B) and wild-type cofilin plus 
either K898R PLD1 (Both) (A) or K758R PLD2 (Both) (B). After 48 h, PLD activity was determined 
in the absence (Basal) and presence of 1 mM carbachol (Carb). Data are representative of three 
similar experiments. 
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The following experiments were set up to gain insights into the mechanisms of PLD 
regulation by cofilin. As regulation of the phosphoinositide metabolism can profoundly affect 
PLD signaling (Liscovitch et al., 2000; Cockcroft, 2001; Exton, 2002) and as Rho-kinase 
regulates PIP 5-kinase activity (Oude Weernink et al., 2000a; Yamazaki et al., 2002), it was 
considered that LIM-kinase and cofilin may affect PLD stimulation via regulation of the 
cellular PIP2 content. To study this, HEK-293 cells were transiently transfected with the 
various LIM-kinase and cofilin mutants, followed by measurements of the cellular PIP2 level. 
As illustrated in Fig. 34, none of the LIM-kinase and cofilin mutants altered the cellular level 
of PIP2 (Fig. 34A). Likewise, the LIM-kinase and cofilin mutants did not change basal and 
carbachol-stimulated IP3 formation (Fig. 34B). Thus, LIM-kinase/cofilin triggers PLD 
stimulation most likely not via modulation of the cellular phosphoinositide metabolism. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 34: LIM-kinase and cofilin do not change cellular PIP2 and PLC signaling. M3 mAChR-
expressing HEK-293 cells were transfected with empty expression vectors (Con), wild-type LIM-
kinase (WT), constitutively active LIM-kinase (CAT, 100 µg each), 150 µg kinase-deficient LIM-
kinase (KD), 100 µg wild-type cofilin (WT) or 150 µg S3A cofilin. After 48 h, either cellular PIP 2 
level was determined in unstimulated cells (A) or IP3 formation was determined in the absence (Basal) 
and presence of 1 mM carbachol (Carb) (B) (n = 3).  
 
 
The interaction of cofilin with actin is tightly controlled by a phosphocycling 
process. Specifically, binding of cofilin to actin, inducing F-actin depolymerization, is lost 
upon phosphorylation of cofilin at serine 3 by LIM-kinase, resulting in F-actin reassembly 
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(Bamburg, 1999; Chen et al., 2000; Higgs & Pollard, 2001; see also Fig. 4). Therefore, it was 
studied whether PLD stimulation by cofilin is controlled its phosphorylation state. For this, 
cofilin was phosphorylated by LIM-kinase, and the effects of unphosphorylated and 
phosphorylated cofilin on the activity of purified recombinant PLD enzymes were studied. As 
shown in Fig. 35B, LIM-kinase phosporylated wild-type cofilin, but not the S3A mutant. 
Addition of purified recombinant wild-type cofilin pretreated with LIM-kinase in the absence 
of MgATP increased the activity of PLD1 by about 50 % (Fig. 35C, upper panel). Most 
important, wild-type cofilin phosphorylated by LIM-kinase (in the presence of MgATP) 
enhanced PLD1 activity by about 300 %. Wild-type cofilin pretreated without LIM-kinase 
was without effect on PLD1 activity (data not shown). Furthermore, neither unphosphorylated 
nor phosphorylated wild-type cofilin altered PLD2 activity (Fig. 35C, lower panel). Finally, 
S3A cofilin, pretreated or not with LIM-kinase in the absence or presence of MgATP, had no 
effect on the activity of either PLD enzyme. Thus, upon phosphorylation by LIM-kinase 
cofilin specifically enhances PLD1 activity.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 35: Phosphorlyated cofilin stimulates PLD1, but not PLD2, in vitro. Schematic illustration of 
cofilin phosphorylation by LIM-kinase and subsequent PLD assay (A). In brief, GST-tagged LIM-
kinase (30 mg,         ) was incubated without and with wild-type cofilin or S3A cofilin (1 mg each,   ) 
in the absence or presence of 1 mM MgATP at 25°C for 45 min. Then, GST-tagged LIM-kinase was 
pelleted, and the supernatant (10 mg protein / sample) was incubated with GST-PLD1 (   )(upper panel) 
or GST-PLD2 (lower panel) (15 µg each) to measure PLD activity (C). GST-tagged LIM-kinase (30 
µg) was incubated with 1 mg wild-type or S3A cofilin in the presence of [g-32P]ATP for 45 min at 
25°C. Phosphorylated cofilin was detected by autoradiography with Kodak X-Omat AR-films (B). 
Data are representative of three experiments. 
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PLD, primarily PLD2, enzyme activity is known to be regulated by actin, actin-
binding proteins as well as proteins involved in synaptic vesicle trafficking, probably due to 
direct interactions (Lee et al., 1997; Jenco et al., 1998; Lee et al., 2000; Park et al., 2000; Lee 
et al., 2001; Ahn et al., 2002; Lee et al., 2002). However, it has to be emphasized that all such 
molecules do inhibit PLD enzyme activity. In contrast, here for the first time a stimulatory 
effect of an actin-binding protein (cofilin) on PLD, specifically PLD1 activity is presented. It 
was, therefore, of interest to study whether cofilin directly interacts with PLD1. As illustrated 
in Fig. 36, wild-type cofilin, but not S3A mutant, specifically bound to PLD1, but not PLD2. 
These data reflect the differential stimulatory effect of wild-type cofilin on PLD1, but not 
PLD2 activity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 36: Cofilin binds to PLD1, but not PLD2, in vitro. Glutathione Sepharose beads loaded with 
GST, GST-PLD1 and GST-PLD2 (20 µg each) were incubated with recombinant His6-tagged wild-
type or S3A cofilin (30 µg each) overnight at 4°C. Specifically bound proteins were separated by 
SDS-PAGE, transferred onto nitrocellulose membrane and detected by immunoblotting with anti-PLD 
and anti-His antibodies. Data are representative of three experiments. 
Anti-PLD1                     Anti-PLD2     
  WT        WT         S3A                  WT        WT           S3A 
               Cofilin                                           Cofilin     
Anti-His                         Anti-His    
  GST       PLD1      PLD1              GST     PLD2       PLD2 
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As wild-type cofilin is able to directly and specifically interact with PLD1 in vitro, 
we transiently transfected HEK-293 cells with PLD and cofilin mutants to analyze by 
immunofluorescence laser confocal microscopy whether cofilin affects subcellular 
localization of PLD enzymes. As reported before in other cell types (reviewed in: Cockcroft, 
2001; Liscovitch et al., 2001; Exton, 2002), in HEK-293 cells PLD1 localized to intracellular 
compartments and the plasma membrane, whereas PLD2 was found exclusively at the plasma 
membrane (Fig. 37; compare A and D). Coexpression of wild-type cofilin altered subcellular 
localization of PLD1 (Fig. 37B). In cells coexpressing PLD1 and wild-type cofilin PLD1 was 
found primarily at the plasma membrane (Fig. 37B). Coexpression of S3A cofilin and PLD1 
did not cause such drastic subcellular redistribution of PLD1 (Fig. 37C). In contrast, 
coexpression of either wild-type or S3A cofilin did not alter the subcellular localization of 
PLD2 (Fig. 37E-F). 
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Fig. 37: Subcellular redistribution of PLD1, but not PLD2, by cofilin. M3 mAChR-expressing 
HEK-293 cells were transfected with wild-type PLD1 (A-C) or wild-type PLD2 (D-F) (50 µg each) 
either alone (A, D), with HA-tagged wild-type cofilin (50 µg) (B, E) or HA-tagged S3A cofilin (150 
µg) (C, F). After 48 h, immunofluorescence laser confocal microscopy was performed as described in 
the "Materials and Methods" section. After incubation with the primary antibodies (anti-PLD or anti-
HA), PLD enzymes were detected with Alexa-633 goat anti-rabbit IgG (excitation: 633; emission: red 
colour) and cofilin with Alexa-488 goat anti-mouse IgG (excitation: 488; emission: green colour). 
Yellow colour: merge of red and yellow colours. Data are characteristic of three similar experiments. 
Control        Wild-type Cofilin    S3A Cofilin  
PLD1 
PLD2 
A                 B                   C      
D                 E                   F      
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5. Discussion 
 
Phosphatidylcholine-specific phospholipase D (PLD) enzymes represent, together 
with the phosphatidylinositol-4,5-bisphosphate (PIP2)-hydrolyzing phospholipase C (PLC) 
isoforms, an extracellular signal-activated phospholipase superfamily, which generates 
biologically active products (Exton, 1999; Liscovitch et al., 2000; Cockcroft, 2001; Rhee, 
2001; Steed & Cow, 2001; Exton, 2002). The hydrolysis of phosphatidylcholine by PLD 
enzymes generates the second messenger phosphatidic acid (PA), which is assumed to trigger 
various early and late cellular responses, such as calcium mobilization, secretion, superoxide 
production, endocytosis, exocytosis, vesicle trafficking, glucose transport, rearrangements of 
the actin cytoskeleton, mitogenesis and apoptosis (see Fig. 1; Daniel et al., 1999; Jones et al., 
1999a; McPhail et al., 1999; Venable et al., 1999; Nakashima & Nozawa, 1999; Liscovitch et 
al., 2000; Exton, 2002; Cummings et al., 2002a; Joseph et al., 2002). These conclusions on 
the cellular role of PLD are mainly based on findings with primary alcohols, which are used 
by PLD enzymes in a PLD-specific transphosphatidylation reaction to produce biologically 
inactive phosphatidylalcohols (see Fig. 2; Morris et al., 1997; Liscovitch et al., 2000; 
Cockcroft, 2001; Exton, 2002). In addition, transfection of catalytically inactive mutants of 
the two PLD enzymes identified in mammalian cells, PLD1 and PLD2, has been successfully 
used to further unravel the physiological role of PLD enzymes (Shen et al., 2001; Denmat-
Ouisse et al., 2001; Humeau et al., 2001; Vitale et al., 2001; Kam & Exton, 2001). However, 
in many mammalian cell types, specifically in primary cultured cells, this approach is often 
hampered due to low transfection efficiencies. Thus, more powerful tools are needed to 
unravel the physiological role of PLD enzymes.  
Infection of mammalian cells by recombinant adenoviruses is a powerful tool to 
characterize the cellular function of proteins encoded by such adenoviruses, as also shown 
here for adenoviruses encoding RGS4 and Lsc-RGS. Using adenoviruses encoding these 
proteins, we even gained insights into the signaling mechanisms of G protein-coupled 
receptors to PLD in cardiomyocytes, a cell type known to be resistant to transfection by 
classical means (Fahimi-Vahid et al., 2002; Gosau et al., 2002). Therefore, for future work on 
the cellular role of PLD enzymes in receptor action, adenoviruses encoding wild-type and 
catalytically inactive PLD1 and PLD2 mutants were generated, using the pAdEasy system 
(He et al., 1998). The PLD adenoviruses successfully infected HEK-293 and PC12 cells, as 
shown by fluoresence microscopy and by immunoblotting with specific antibodies. In 
preliminary studies, it was observed that infection of PC12 cells with the adenoviruses 
encoding the PLD enzymes differentially affects agonist-triggered noradrenaline release (data 
not shown). While this work was in progress, Wang et al. (2002) reported the generation of 
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the same PLD adenoviruses and showed that infection of human bronchial epithelial cells 
with adenoviruses encoding PLD1 and PLD2 differentially alters receptor-mediated ERK 
activation and interleukin-8 secretion. Thus, the generated adenoviruses encoding wild-type 
and catalytically inactive PLD1 and PLD2 mutants will most likely provide a powerful tool 
for future work on the physiological role of PLD enzymes, specifically in primary cultured 
cells. 
Activation of PLD enzymes by membrane receptors has been demonstrated in 
numerous cell types with a wide variety of hormones, neurotransmitters and growth factors 
(Exton, 1999; Liscovitch et al., 2000; Cockcroft, 2001; Exton, 2002). However, in contrast to 
PLC isoforms, where direct interaction with membrane receptors and/or their associated 
heterotrimeric G proteins is needed and sufficient for activation (Schlessinger, 2000; Rhee, 
2001), PLD enzymes are not directly activated by receptors or heterotrimeric G proteins (Min 
et al., 1998; Slaaby et al., 1998). Consequently, additional signaling molecules have been 
searched and analyzed for their potential involvement in receptor signaling to PLD. Among 
the signaling molecules meanwhile identified to be involved in receptor signaling to PLD 
enzymes are phosphoinositides, particularly PIP2, members of various monomeric GTPase 
families, specifically ARF, Rho and Ras GTPases, and protein kinases, specifically protein 
kinase C (PKC) isoforms and the Rho-activated Rho-kinase (reviewed in: Exton, 1999; 
Liscovitch et al., 2000; Cockcroft, 2001; Exton, 2002). Despite the large body of information 
accumulated so far, our knowledge about receptor coupling mechanisms to PLD enzymes is 
still far from being complete. 
As nearly every membrane receptor, either G protein-coupled or tyrosine kinase 
receptor, known to stimulate PIP2-specific PLC isoforms also causes PLD stimulation, it was 
assumed that stimulation of PLD ensues from PLC activation, with subsequent increase in 
cytosolic Ca2+ concentration and activation of PKC isoforms. In line with this assumption, it 
was shown that coexpression of bombesin and M1 or M3 muscarinic acetylcholine receptors 
(mAChRs), known to stimulate PLC via the pertussis toxin (PTX)- insensitive Gq family of 
heterotrimeric G proteins (Neer, 1995; Gudermann et al., 1996; Caulfield & Birdsall, 1998; 
Watling, 2001), with PKC-unresponsive PLD1 mutants fully blunts the receptor-mediated 
PLD stimulation (Zhang et al., 1999; Du et al., 2000). Similarly, expression of a PKC-
unresponsive PLD1 mutant in COS-7 cells suppressed PLD stimulation by a coexpressed 
constitutively active Gaq mutant (Xie et al., 2002). However, the PLD response to a1-
adrenoceptor activation in Mardin-Darby canine kidney cells was PKC-independent (Kiss, 
1996; Balboa & Insel, 1998), similarly as PLD stimulation by noradrenaline in rabbit aortic 
vascular smooth muscle cells (Muthalif et al., 2000; Parmentier et al., 2001). Thus, PLD 
stimulation by membrane receptors must not necessarily be secondary to PLC stimulation. 
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The G protein-coupled M3 mAChR, stably expressed in HEK-293 cells, efficiently 
stimulates both, PLC and PLD, in a PTX-insensitive manner (Peralta et al., 1988; Offermanns 
et al., 1994; Schmidt et al., 1994). However, stimulation of PLD by the agonist carbachol was 
found to be independent of concomitant increases in cytosolic Ca2+ concentration and  
activation of PKC isoforms, thus apparently not secondary to PLC stimulation (Schmidt et al., 
1994; Rümenapp et al., 1997). The M3 mAChR couples to PLC apparently via Gq-type G 
proteins (Offermanns et al., 1994; Rhee, 2001). As it has been recently demonstrated in 
cotransfection experiments that both Gq- and G12-type G proteins can cause PLD stimulation 
(Plonk et al., 1998; Ushio-Fukai et al., 1999; Xie et al., 2002), it was considered that the 
receptor couples to PLC and PLD via the same type of G protein, i.e. Gq, or that two distinct 
G proteins, Gq and G12, mediate receptor coupling to the two phospholipases. The Gq- and 
G12-type G proteins are both not PTX substrates (Neer, 1995; Dhanasekaran & Dermott, 1996; 
Fields & Casey, 1997). Thus, PTX treatment of cells cannot be used to discriminate between 
these two types of G proteins. Regulators of G protein signaling (RGS) act as GTPase-
activating proteins (GAPs) for heterotrimeric G proteins and thereby terminate the response 
responses, such as PLC stimulation. As different members of the RGS proteins exhibit Ga-
subunit specificity (Druey et al., 1996; Dohlman & Thorner, 1997; Huang et al., 1997; Neill 
et al., 1997; Wieland & Chen, 1999; de Vries et al., 2000; Ross & Wilkie, 2000), expression 
of these proteins should help to define the G protein subtype involved in M3 mAChR 
signaling to PLD.  
Using this approach as well as expression of the relevant Ga-subunits (wild-type 
and mutants), it is shown herein that the M3 mAChR signals to PLC and PLD via two distinct 
types of G proteins, i.e. Gq and G12, respectively. Specifically, it is demonstrated that 
expression of constitutively active Gaq induced a strong receptor- independent increase in 
PLC activity. Additional work demonstrated that the M3 mAChR signals via Gaq to PLC-b1 
(Evellin et al., 2002). In contrast, expression of constitutively active Gaq had no effect on 
PLD activity, which, however, was strongly enhanced upon coexpression of constitutively 
active Ga12 and Ga13, suggesting that both G12-type G proteins, G12 and G13, are required for 
full PLD stimulation. This hypothesis was corroborated by expression of dominant-negative 
mutants of Ga12 or Ga13 (Gohla et al., 1999), which reduced PLD stimulation by the M3 
mAChR to a similar extent. The data obtained with the expression of the Ga mutants were 
confirmed by expression (transient or by infection with recombinant adenoviruses) of RGS4 
or Lsc-RGS, which act as specific GAPs for Gaq- and Ga12-type G proteins, respectively. In 
detail, expression of RGS4 specifically blunted the PLC response to the M3 mAChR, whereas 
expression of Lsc-RGS specifically diminished receptor signaling to PLD. As expected, 
adenoviral infection induced a more efficient gene transfer (He et al., 1998; Young & 
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Mautner, 2001; Armstrong et al., 2002) and consequently a more drastic inhibition of the 
receptor responses. Meanwhile, the adenoviruses encoding RGS4 and Lsc-RGS have been 
successfully used to characterize the type of G proteins involved in receptor signaling to PLD 
in cardiomyocytes (Fahimi-Vahid et al., 2002; Gosau et al., 2002).  
Expression of either Ga-subunit mutants or RGS proteins did not alter PLD 
stimulation by phorbol 12-myristate 13-acetate (PMA)-responsive PKC. These findings 
confirmed the quite remarkable, differential involvement of distinct heterotrimeric G proteins 
in M3 mAChR signaling to PLC and PLD. It has been demonstrated previously that the PLD 
response to PMA-responsive PKC in HEK-293 cells is triggered by tyrosine kinase receptors 
for epidermal growth factor, platelet-derived growth factor and insulin (Schmidt et al., 1998; 
Voß et al., 1999). Taken together, the findings reported here strongly corroborate the idea that 
in HEK-293 cells stimulation of PLD by the M3 mAChR is in fact not a consequence of the 
concomitant PLC stimulation. However, the M3 mAChR induces PLC stimulation with 
subsequent PKC activation (Voß et al., 1999; Rümenapp et al., 2001), but stimulation of PLD 
is apparently independent of this reaction. Thus, it is assumed that the M3 mAChR assembles 
together with G12-type G proteins and PLD into a highly organized signaling complex at the 
plasma membrane. Indeed, PLD enzymes were recently found to be present in caveolae 
(Czarny et al., 1999; Sciorra & Morris, 1999), which in concert with lipid rafts are believed to 
confer specificity into the complex mechanisms of signal transduction (Okamoto et al., 1998; 
Kurzchalia & Parton, 1999; Anderson & Jacobson, 2002; Zajchowski & Robbins, 2002). 
As PLD stimulation in HEK-293 cells by the G protein-coupled M3 mAChR and the 
tyrosine kinase receptors obviously involves distinct signaling cascades (Schmidt et al., 1994; 
Rümenapp et al., 1995; Schmidt et al., 1996b; Schmidt et al., 1999; Voß et al., 1999), these 
cells represent an ideal model system to study a possible differential receptor signaling to 
PLD1 and PLD2 enzymes. It is demonstrated here, by expression of catalytically inactive 
PLD1 and PLD2 mutants, that the M3 mAChR signals to PLD1, whereas the tyrosine kinase 
receptors signal via PKC to PLD2. Previous reports have also provided evidence that PLD1 
and PLD2 are differentially affected by G protein-coupled and tyrosine kinase receptors, 
respectively (Zhang et al., 1999; Du et al., 2000; Slaaby et al., 1998; Slaaby et al., 2000). 
However, it has to be emphasized that these results were obtained in cotransfection studies 
and thus may not mimic the native cellular setting.  
In previous studies, it was shown that PLD stimulation by the M3 mAChR requires 
Rho GTPases, specifically RhoA. Although Rho proteins can directly interact with and 
activate PLD1 (Hammond et al., 1997; Sung et al., 1999b; Frohman, et al., 2000; Cai & 
Exton, 2001), PLD stimulation by RhoA in HEK-293 cells was apparently not due to such a 
direct interaction. Additional work demonstrated that RhoA-dependent stimulation of PIP 5-
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kinase, causing an increase in the cellular content of PIP2, which acts as an essential cofactor 
to maintain receptor signaling to PLD, is involved in PLD stimulation (Schmidt et al., 1996; 
Schmidt et al., 1996c; Schmidt et al., 1999; Oude Weernink et al., 2000a). Furthermore, Rho-
kinase, a Rho effector protein, was identified as an essential element in the M3 mAChR 
signaling cascade to PLD (Schmidt et al., 1999). However, PLD enzymes did not directly 
interact with, or were phosphorylated by Rho-kinase (Schmidt et al., 1999). Thus, regulation 
of PLD by Rho/Rho-kinase obviously involves additional, yet undefined, signaling 
components. Here, LIM-kinase, a Rho-kinase effector (Lim et al., 1996; Maekawa et al., 1999; 
Sumi et al., 2001a), is identified as a novel player in G protein-coupled receptor signaling to 
PLD. Expression of wild-type and constitutively active LIM-kinase potentiated PLD 
stimulation by the M3 mAChR, similar to overexpression of RhoA and Rho-kinase (Schmidt 
et al., 1999), whereas expression of kinase-deficient LIM-kinase largely reduced PLD 
stimulation by the receptor. The LIM-kinase mutants did not alter basal PLD activity and 
PLD stimulation by PMA-responsive PKC. Furthermore, purified recombinant LIM-kinase 
enhanced PLD activity in membranes of HEK-293 cells, similar as but not additive with 
activated RhoA or Rho-kinase. These findings suggested that LIM-kinase mediates PLD 
stimulation by Rho and Rho-kinase. In line with this hypothesis, it is demonstrated that PLD 
potentiation by wild-type LIM-kinase, but not by constitutively active LIM-kinase, is 
suppressed by coexpression of the Rho- inactivating C3 transferase (Aktories & Just, 1993) 
and a dominant-negative Rho-kinase mutant (Oshiro et al., 1998). In contrast, expression of 
dominant-negative Rac1 and Cdc42 mutants did not alter the PLD response to the M3 mAChR 
and LIM-kinase. These findings indicate that even the action of the overexpressed LIM-
kinase is under tight control by endogenous Rho. Furthermore, expression of kinase-deficient 
LIM-kinase fully prevented PLD activation by both wild-type and constitutively active Rho-
kinase. Finally, expression of catalytically inactive PLD1, but not of catalytically inactive 
PLD2, abolished PLD potentiation by LIM-kinase. Thus, overall, LIM-kinase is identified 
here as a novel component acting downstream of RhoA and Rho-kinase in G protein-coupled 
receptor signaling to PLD1. 
Expression of constitutively active LIM-kinase, which is unresponsive to Rho/Rho-
kinase-dependent phosphorylation at threonine 508 (Edwards & Gill, 1999), strongly 
enhanced the stimulatory effect of the agonist-activated M3 mAChR but did not cause an 
increase in basal PLD activity. These findings indicated that a second signal, which is 
apparent ly provided by the agonist-activated receptor, is required to gain full PLD activation. 
Based on previous data (Rümenapp et al., 1995; Schmidt et al., 1996b; Schmidt et al., 1999; 
Schürmann et al., 1999; Voß et al., 1999), this second signal required for PLD activation is 
the ARF pathway. In fact, it is demonstrated here that coexpression of dominant-negative 
ARF1 fully blocks PLD potentiation by constitutively active LIM-kinase, and vice versa 
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coexpression of kinase-deficient LIM-kinase fully prevents PLD potentiation by 
constitutively active ARF1. Thus, stimulation of PLD by the G protein-coupled receptor M3 
mAChR is apparently a concerted action of ARF and Rho signaling pathways, the latter 
involving Rho-activated Rho-kinase and its downstream effector, LIM-kinase (Fig. 38). 
Whether and how these two pathways are interconnected is presently not known. The recently 
identified ARAP proteins, which are apparently involved in regulation of both ARF and Rho 
GTPases (Krugmann et al., 2002; Miura et al., 2002), are possible candidates where these two 
may converge. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 38: M3 mAChR signaling to PLD1 mediated by G12-type G proteins, LIM-kinase 
and cofilin. For further explanation, see text. 
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Expression of kinase-deficient LIM-kinase not only suppressed PLD stimulation by 
the overexpressed M3 mAChR in HEK-293 cells, but similarly reduced PLD stimulation by 
the endogenously expressed receptor for lysophosphatidic acid, while it had no effect on PLD 
stimulation by tyrosine kinase receptors. Furthermore, expression of the LIM-kinase mutants 
altered PLD stimulation by an endogenously expressed mAChR in N1E-115 neuroblastoma 
cells similarly as observed for the overexpressed M3 mAChR in HEK-293 cells. These data 
strongly suggest that LIM-kinase plays a general role in PLD stimulation by G protein-
coupled receptors. Very recently, the generation of a LIM-kinase knockout mice has been 
reported (Meng et al., 2002). Studies are in progess to examine regulation of PLD signaling in 
cells and tissues from these LIM-kinase knockout mice.  
LIM-kinase did not directly interact with either PLD1 or PLD2 and did not 
phosphorylate these PLD enzymes, suggesting that LIM-kinase may regulate PLD activity via 
an additional cellular component. Here it is demonstrated that cofilin, a member of the actin 
depolymerization family and a substrate of LIM-kinase (Bamburg, 1999; Maekawa et al., 
1999; Higgs & Pollard, 2001), obviously represents the missing signaling molecule. 
Expression of wild-type cofilin enhanced M3 mAChR signaling to PLD1, and this stimulatory 
effect required a functional Rho/Rho-kinase/LIM-kinase signaling cascade. In contrast, the 
LIM-kinase nonphosphorylatable cofilin mutant, S3A cofilin, reduced PLD stimulation by the 
M3 mAChR and its potentiation by LIM-kinase. The cofilin mutants were without effect on 
basal PLD activity and PLD stimulation by PMA-activated PKC. Thus, we have identified 
cofilin as the downstream effector of LIM-kinase in the activation of PLD1 by Rho and Rho-
kinase (Fig. 38). 
In contrast to Rho-kinase, which stimulates PIP 5-kinase activity (Oude Weernink et 
al., 2000b; Yamazaki et al., 2002), LIM-kinase and cofilin did not alter the cellular PIP2 
levels. These data suggested that LIM-kinase and cofilin did not trigger PLD stimulation 
indirectly, i.e. by providing its cofactor PIP2. In contrast, it is demonstrated here that wild-
type cofilin, but not S3A cofilin, specifically binds to PLD1 and triggers its enzyme activity, 
particularly upon phosphorylation by LIM-kinase. Furthermore, expression of wild-type 
cofilin induced redistribution of coexpressed PLD1 to the plasma membrane of HEK-293 
cells. Thus, it is tempting to speculate that cofilin phosphorylated by LIM-kinase increases 
PLD1 activity by targeting the phospholipase to this cellular compartment, which also bears 
Rho and ARF proteins after stimulation of the cells by the M3 mAChR (Rümenapp et al., 
1995; Keller et al., 1997). 
As schematically illustrated in Fig. 38, apparently many distinct proteins are 
involved in stimulation of PLD1 activity by the G protein-coupled M3 mAChR. However, this 
may not be the end. Several additional proteins have been recently identified to be regulated 
by LIM-kinase and/or to modulate the function of cofilin. These include the collapsin 
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response mediator protein-2, wich is known to be involved in the LIM-kinase-dependent 
regulation of the actin growth cone in neuronal cells (Aizawa et al., 2001a; Liu & Strittmatter, 
2001) and which has actually been reported to inhibit PLD activity in neuronal cells (Lee et 
al., 2002). Furthermore, the scaffold protein 14-3-3 has recently been shown to modulate 
LIM-kinase and cofilin signaling by stabilizing phosphorylated cofilin (Gohla & Bokoch, 
2002; Birkenfeld et al., 2002). Finally, phosphatases have recently been identified which may 
also be involved in PLD signaling, such as the slingshot phosphatase, which binds F-actin and 
specifically dephosphorylates cofilin (Niwa et al., 2002), and protein phosphatase type 5, 
which is stimulated by Ga12 and Ga13 (Yamaguchi et al., 2002), the G proteins mediating G 
protein-coupled receptor signaling to PLD. Studies are in progress to analyze whether these 
signaling molecules contribute to PLD regulation by membrane receptors.  
In summary, evidence is provided that stimulation of PLD activity by G protein-
coupled receptors, already known to involve ARF and Rho GTPases and the Rho-activated 
Rho-kinase, is mediated specifically by heterotrimeric G proteins of the G12-subtype (Ga12 
and Ga13), the Rho-kinase effector, LIM-kinase, and the LIM-kinase substrate, cofilin, which 
apparently in its phosphorylated form interacts with and stimulates PLD1 activity. Finally, 
adenoviruses encoding PLD1 and PLD2 (wild-type and mutants) have been generated, which 
will provide powerful tools to study the physiological function of the distinct PLD enzymes. 
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6. Synopsis 
 
Stimulation of phosphatidylcholine-specific phospholipase D (PLD) enzymes, 
leading to the generation of the second messenger, phosphatidic acid, has been demonstrated 
in numerous cell types with a large number of hormones, neurotransmitters and growth 
factors and is implicated in a wide array of early and late cellular responses to receptor 
activation. In contrast to the stimulation of phosphatidylinositol-4,5-bisphosphate (PIP2)-
specific phospholipase C (PLC) isoforms, which is caused by a direct interaction with 
receptors and/or heterotrimeric G proteins, activation of the PLD enzymes by membrane 
receptors is mediated by complex signaling cascades, involving lipids and proteins of diverse 
families. The most important are the phosphoinositide, PIP2, members of the monomeric 
GTPases superfamily, specifically ARF, Rho and Ras GTPases, and diverse protein kinases, 
specifically protein kinase C (PKC) isoforms and the Rho-activated Rho-kinase. However, 
our understanding of receptor coupling to PLD enzymes is still rather incomplete.  
Aim of the present study was to gain further insights into the regulation of PLD 
activity by G protein-coupled receptors, using HEK-293 cells stably expressing the M3 
muscarinic acetylcholine receptor (mAChR). Previous work demonstrated that the M3 
mAChR stimulates PLD in a pertussis toxin (PTX)- insensitive manner, and that stimulation of 
PLD is independent of concomitant PLC and subsequent PKC activation. Additional work 
indicated that the PLD response to the M3 mAChR requires ARF and Rho GTPases and the 
Rho-activated Rho-kinase. On the other hand, tyrosine kinase receptor signaling to PLD in 
HEK-293 cells is PKC-dependent and involves a Ras/Ral GTPases signaling cascade. 
First, the type of PTX-insensitive heterotrimeric G protein mediating M3 mAChR-
PLD coupling versus M3 mAChR-PLC coupling was determined. By transient expression of 
a-subunits of the PTX-resistant G proteins, Gq,  G12 and G13 (wild-type, constitutively active 
and dominant-negative mutants), evidence is provided that the M3 mAChR specifically 
couples to PLC via Gaq and to PLD via the G12-type G proteins, Ga12 and Ga13, which are 
apparently both required for full PLD stimulation. These data were confirmed by expression 
(transient or by infection with recombinant adenoviruses) of RGS4 or Lsc-RGS, which act as 
specific GTPase-activating proteins for Gaq- and Ga12-type G proteins, respectively.  
Second, the PLD isoform activated by membrane receptors in HEK-293 cells was 
determined. Expression of catalytically inactive PLD1 and PLD2 mutants strongly suggested 
that the G protein-coupled M3 mAChR signals primarily to PLD1, whereas the tyrosine kinase 
receptors signal via PKC to PLD2. For further analysis of the cellular function of the PLD 
enzymes, recombinant adenoviruses encoding wild-type and catalytically inactive PLD1 and 
PLD2 mutants were generated, using the pAdEasy system. Infection of cells with these 
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adenoviruses led to strong expression of the PLD enzymes, indicating that the PLD-encoding 
adenoviruses can be used in future studies to define the physiological role of the distinct PLD 
enzymes in mammalian cells. 
PLD enzymes are not phosphorylated by Rho-kinase, indicating that regulation of 
PLD by Rho/Rho-kinase involves additional, yet undefined, components. Here evidence is 
provided that LIM-kinase, a Rho-kinase effector, mediates the Rho/Rho-kinase-dependent 
stimulation of PLD1. Expression of wild-type and constitutively active LIM-kinase 
potentiated PLD stimulation by the M3 mAChR, whereas kinase-deficient LIM-kinase had the 
opposite effect. Similar data were obtained with other G protein-coupled receptors in HEK-
293 and N1E-115 neuroblastoma cells. On the other hand, the LIM-kinase mutants did not 
alter PLD stimulation by phorbol ester-activated PKC and tyrosine kinase receptors. Purified 
recombinant LIM-kinase stimulated PLD activity in cell membranes, similar as but not 
additive with activated RhoA or Rho-kinase. In line with a downstream effector role of LIM-
kinase, PLD stimulation by constitutively active LIM-kinase, but not by wild-type LIM-
kinase, was resistant to inactivation of Rho and Rho-kinase, whereas PLD stimulation by 
constitutively active Rho-kinase was fully abolished by kinase-deficient LIM-kinase. Thus, 
LIM-kinase is a downstream effector of Rho-kinase to gain full activation of PLD1 by Rho-
dependent signals initiated by G protein-coupled receptors. 
Stimulation of PLD by the M3 mAChR is apparently the result of two signaling 
cascades mediated by ARF and Rho GTPases. In line with this dual signaling process, 
expression of dominant-negative ARF1 fully blocked PLD stimulation by constitutively 
active LIM-kinase, and vice versa coexpression of kinase-deficient LIM-kinase fully 
prevented PLD potentiation by constitutively active ARF1. Thus, in HEK-293 cells 
stimulation of PLD1 by the M3 mAChR is a concerted action of a Rho/Rho-kinase/LIM-
kinase and an ARF signaling cascade.  
As reported for Rho-kinase, LIM-kinase did not directly interact with nor did LIM-
kinase phosphorylate PLD enzymes, suggesting that an additional component is involved in 
PLD regulation by Rho-kinase/LIM-kinase. Here evidence is provided that the LIM-kinase 
substrate, cofilin, an actin depolymerization factor, in its phosphorylated form directly 
interacts with PLD1 and increases PLD1 activity. Expression of wild-type cofilin potentiated 
PLD stimulation by the M3 mAChR, whereas the nonphosphorylatable cofilin mutant, S3A 
cofilin, reduced the receptor response. On the other hand, the cofilin mutants did not alter 
PLD2 stimulation by phorbol ester-activated PKC. Furthermore, PLD stimulation by cofilin 
was suppressed by inactivation of Rho or Rho-kinase. Finally, it is shown that cofilin, but not 
its S3A mutant, specifically interacts with PLD1 and, upon phosphorylation by LIM-kinase, 
strongly increases the activity of purified recombinant PLD1 in vitro. In intact cells, 
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expression of wild-type cofilin, but not S3A cofilin, specifically redistributed PLD1 to the 
plasma membrane, as demonstrated by immunofluorescence laser confocal microscopy. 
Taken together, evidence is provided that stimulation of PLD by G protein-coupled receptors, 
known to involve ARF and Rho GTPases and the Rho-activated Rho-kinase, is mediated 
specifically by heterotrimeric G proteins of the G12-subtype (Ga12 and Ga13), the Rho-kinase 
effector, LIM-kinase, and the LIM-kinase substrate, cofilin, which apparently in its 
phosphorylated form interacts with and stimulates PLD1 activity. 
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